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A multi-resistência a antibióticos e medicamentos usados em quimioterapia é um dos grandes 
problemas com os quais as instituições de saúde se debatem hoje em dia. A acção provocada por 
bombas de efluxo é uma das suas causas. Estas bombas têm uma importância fundamental, uma vez 
que, ao expelirem todo o tipo de tóxicos para o exterior das células, também expelem 
medicamentos, fazendo com que estes não tenham o efeito desejado dentro delas.  
As bombas de efluxo são transportadores que se encontram nas membranas de todo o tipo de 
células. Existem dois grandes tipos de bombas de efluxo: as primárias e as secundárias. As 
primeiras conferem multi-resistência principalmente em células eucariotas, como as células do 
cancro em humanos, tendo como função a mediação da repulsa de substâncias tóxicas por 
intermédio da hidrólise de ATP.  A primeira a ser descoberta e mais estudada destas bombas foi a 
ABCB1 que é o gene que codifica a glicoproteína-P (P de permeabilidade). Enquanto as 
secundárias, que são a maior fonte de multi-resistência em bactérias, promovem a extrusão de 
substâncias tóxicas através da força motriz de protões. Neste tipo de bombas são conhecidas quatro 
famílias principais, das quais uma das mais importantes é a superfamília RND, uma vez que inclui a 
bomba AcrAB-TolC, que é muito importante no metabolismo xenobiótico de bactérias Gram-
negativas, nomeadamente a E.coli. 
Com o objectivo de reverter a multi-resistência, tanto em células eucariotas como procariotas, têm-
se desenvolvido estratégias de combate que envolvem a descoberta de substâncias que inibam as 
bombas de efluxo. Assim sendo, ao longo dos tempos têm sido descobertas variadas substâncias 
que cumprem este objectivo. É o caso, por exemplo, dos derivados de fluoroquinolonas usados 
como inibidores de bombas de efluxo em bactérias ou do Tamoxifen, utilizado na terapia de 
pacientes com cancro da mama. 
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Um dos grupos de substâncias estudados para o desenvolvimento de possíveis compostos que 
actuem como reversores de multi-resistência são os compostos derivados de hidantoínas. Estes, são 
conhecidos por possuírem uma grande variedade de propriedades bioquímicas e farmacológicas, 
sendo portanto usados para tratarem algumas doenças em humanos, como a epilepsia. Nestes, estão 
englobados compostos com actividade anti-convulsão que constitui a sua grande mais-valia e, 
dependente da substituição no anel que os constitui, uma grande variedade de outras propriedades 
farmacológicas como a anti-fungica, a anti-arritmica, a anti-viral, a anti-diabética ou por exemplo a 
antagonização de determinados receptores, como os da serotonina. Apesar de pouco usados em 
estudos experimentais para desenvolver substâncias anti-carcinogénicas, existem alguns estudos 
com este efeito.  
Objectivos: O presente projecto envolve o estudo de bombas de efluxo primárias e secundárias, em 
células eucariotas e procariotas, respectivamente. Em bactérias, foram usados quatro modelos 
experimentais: Staphylococcus aureus ATCC 25923, Enterococcus faecalis ATCC 29212, E. coli 
AG 100 e Salmonella Enteritidis NCTC 13349. Em células de cancro foram usadas, células T de 
linfoma de rato parentais e células T de linfoma de rato transfectadas com o gene humano MDR-1. 
O principal objectivo deste estudo foi a pesquisa de novos moduladores de bombas de efluxo 
presentes em bactérias e células do cancro, tentando assim contribuir para o desenvolvimento de 
novos agentes farmacológicos que consigam reverter a multi-resistência a medicamentos. Assim 
sendo foram testados trinta compostos derivados de hidantoínas: SZ-2, SZ-7, LL-9, BS-1, JH-63, 
MN-3, TD-7k, GG-5k, P3, P7, P10, P11, RW-15b, AD-26, RW-13, AD-29, KF-2, PDPH-3, 
Mor-1, KK-XV, Thioam-1, JHF-1, JHC-2, JHP-1, Fur-2, GL-1, GL-7, GL-14, GL-16, GL-18. 
Como forma de atingir estes objectivos, a actividade biológica dos trinta compostos derivados de 
hidantoínas foi avaliada nas quatro estirpes de bactérias da seguinte forma: foram determinadas as 
concentrações mínimas inibitórias dos trinta compostos como forma de definir as concentrações em 
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que os compostos seriam utilizados. Os compostos foram posteriormente testadas com um método 
fluorométrico de acumulação de brometo de etídeo, que é um substrato comum em bombas de 
efluxo bacterianas, desenvolvido por Viveiros et al.  
A actividade biológica dos compostos derivados de hidantoínas nas células de cancro foi 
demonstrada por diferentes métodos. O efeito anti-proliferativo e citotóxico dos trinta compostos 
foi avaliado nas células T de linfoma de rato transfectadas com o gene humano MDR-1 pelo método 
de thiazolyl de tetrazólio (MTT). Como o brometo de etídeo também é expelido pelos 
transportadores ABC, estes compostos foram posteriormente testados com um método 
fluorométrico de acumulação de brometo de etídeo desenvolvido por Spengler et al nos dois 
diferentes tipos de  células eucariotas.  
Resultados: A maioria dos compostos derivados de hidantoínas foi eficaz na modulação de bombas 
de efluxo, nas duas estirpes de bactérias Gram-negativas e nos dois diferentes tipos de células T de 
linfoma. Em contraste com estes resultados, nas duas estirpes de células Gram-positivas, a maioria 
dos compostos tiveram pouco efeito na inibição de bombas de efluxo ou até nenhum, em muitos dos 
casos. De uma maneira geral os melhores compostos nas diferentes estirpes de bactérias foram: 
Thioam-1, SZ-2, P3, Rw-15b, AD-26, AD-29, GL-18, GL-7, KF-2, SZ-7, MN-3, GL-16 e GL-
14. Foram portanto estes os compostos que provocaram maior acumulação de brometo de etídeo, 
inibindo assim com maior eficácia as bombas de efluxo. 
No presente estudo, a maioria dos compostos conseguiu inibir a resistência provocada pela bomba 
de efluxo ABCB1, tanto nas células parentais bem como nas células que sobre-expressam esta 
bomba, causando a acumulação de brometo de etídeo dentro das células. As células que sobre-
expressam a bomba ABCB1 foram posteriormente testadas com citometria de fluxo que é a técnica 
padrão para pesquisa de inibidores de bombas de efluxo. 
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Os compostos que foram mais efectivos na inibição da bomba ABCB1, causando assim maior 
acumulação de brometo de etídeo nas células que sobre-expressam esta bomba foram: PDPH-3, 
GL-7, KK-XV, AD-29, Thioam-1, SZ-7, KF-2, MN-3, RW-13, LL-9, P3, AD-26, JH-63 e RW-
15b. Este facto não corroborou totalmente os resultados da citometria de fluxo uma vez que os 
moduladores que provocaram maior inibição da bomba ABCB1 foram o MN-3, JH-63 e o BS-1, 
sendo que o último não foi seleccionado como um bom composto usando o método fluorométrico 
de acumulação de brometo de etídeo.  
Conclusão: Os compostos derivados de hidantoínas testados tiveram maior efeito nas estirpes de 
bactérias Gram-negativas do que nas Gram-positivas. Relativamente às células eucariotas, as 







I – INTRODUCTION 
1. Historical background of the control of bacterial infections 
In spite of the great efforts on health development, to combat infectious diseases is one of the great 
concerns of health care institutions. Taking in consideration the United Nations Millenium 
objectives, one of the most important needs for human populations is the fight against these 
microorganisms, reducing thus the deaths of thousands of lives (WHO). From their discovery, more 
or less sixty years ago, antibiotics played a huge role in the development of medicine, contributing 
astonishingly to the wellbeing and evolution of the society, becoming thus one of the pillars of 
modern medicine (MILLER et al, 2008).  
In the year of 1546, Hieronymus Fracastorius published a book called “De cotagione”, where he 
described three modes of disease spread: direct contact with infected persons, indirect contact with 
fomites and airborne transmission. In the XIX century, Ignaz Philipp Semmelweis, endeavoured the 
practise of hands washing before surgeries in order to reduce the spread of infection, which was the 
start of antiseptic prophylaxis. These measures were not well received at that time; however many 
deaths by hospital gangrene would have been avoided. It was in the end of the XIX century when 
infection control measures, such as hands washing or boiling of surgical instruments before use 
started to be common (nobelprize.org).  
In 1864, Pasteur, with his work on fermentation, unveiled the role of microorganisms as agents of 
infectious disease. Shortly after, Joseph Lister was the first to denote the connection between 
Pasteur’s work and the suppuration of wounds in surgical settings. In 1867 he published his work 
on antisepsis and then started to apply carbolic acid to open fractures. With this new measure, the 




Paul Ehrlich is one of the greatest contributors to the research on infectious diseases.  In the 
beginning of the XX century he presented an idea in his doctoral thesis: “The chemical constitution 
of drugs used must be studied in relation to their mode of action and their affinity for the cells of the 
organisms against which they were directed”. In collaboration with Hata, he tested a drug on 
syphilis-infected rabbits that was very effective and known under the name Salvarsan (SYKES, 
2010). 
In 1929, Sir Alexander Fleming was searching for potential antibacterial compounds. He noted that 
a patch of the mould Penicillium notatum could grow on a Staphylococcus plate. He also denoted 
that around the mould, the Staphylococcus strain could not grow. However, just Ernst Chain and 
Howard Florey could make the mass production of penicillin possible. The substance, highly 
effective against some of the most prevalent infectious agents, was then used in World War II, 
saving thousands of lives. This discovery remains one of the most remarkable advents in medicine. 
In parallel, Gerhard Domagk discovered the first synthetic molecule, a sulphonamide derivative 
with antibacterial properties. He used this drug to cure his daughter’s streptococcal infection, 
revealing thus the powerful properties of the sulphonamide derivative, which came into clinical 
usage in the 30’s, under the name Prontosil. Both penicillin and prontosil discoveries paved the way 
to the advent of more natural and synthetic antibiotics (SYKES, 2010; TODAR, 2004).  
Previously, in the XX century, an antibiotic was defined as a chemical substance that was produced 
by a microorganism and, in dilute solutions, could inhibit the growth of other microorganisms. That 
definition was then broaden in order to include similar inhibitory substances produced not solely by 
microorganisms. Today, the antibiotics combined with improvements in sanitation, housing and 
nutrition alongside the advent of widespread vaccination programs, have led to a dramatic drop in 
the once common infectious diseases that formerly killed lots of people. Since 1977, the WHO has 
been publishing the so called Model Lists of Essential Drugs, regularly updated, which have been of 
great help, decreasing the number of malpractices regarding antimicrobial therapy (WHO). 
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However, the world has been assisting to the re-emergence of infectious diseases, mainly because of 
the increasing antibiotic resistance. The key factors driving this threat are the following: migration 
of people, animals and goods, increased industrialization and increased antibiotic usage (HAWKEY 
& JONES, 2009). While in the most developed countries the problem is related to the overuse and 
abuse of antibiotics (agriculture, tetracyclines in animal husbandry), in poorer countries it is related 
to the lack of proper medication (WHO). 
In order to overcome the emerging antibiotic resistance, the World Health Organization launched 
the WHO Global Strategy for Containment of Antimicrobial Resistance. This strategy is directed to 
reduce the spread of resistance in various ways. The interventions should be centered in groups of 
people whose behavior contribute to resistance, which have significant impact at both national and 
international levels. These interventions are thus directed to people and institutions as well, e.g. 
from the pharmaceutical industry to consumers and managers of hospitals. On the other hand, the 
introduction of legislation governing the development, licensing, distribution and sale of 
antimicrobials is also of great importance (WHO). 
 
2. Antibiotics and their importance to human medicine 
2.1 Importance of the discovery of antibiotics 
Physicians around the globe have realized soon that bacteria might become resistant to antibiotics. 
Concomitant with the first description of the clinical use of penicillin there was a report of an 
enzyme (named penicillinase) that conferred resistance to penicillin (HAWKEY, 2008a).  But at 
that time, a period of ever more number of successfully introduced drugs into clinical practice, it 
was not too much alarming. The 1940’s and 1950’s were the most prolific to the antibiotics 
discovery, with the introduction of several classes of drugs: aminoglycosides, β-lactams, 
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chloramphenicol, tetracycline, macrolides, glycopeptides, streptogramins and lincosamides. 
Rifamycin and nalidixic acid have been used since the 1960’s. The arrival of new classes of 
therapeutically useful antibiotics lasted two more decades: oxazolidinones (linezolid) and 
lipopetides (daptomycin) (ECKER & CHIBA, 2010; REDDY et al, 2009).  
The accelerated resistance of important human pathogens has been the main cause for the lack of 
antibiotics discovery. The increasing morbidity and mortality rates associated with bacterial 
infections are some of the consequences (HAWKEY & JONES, 2009; SAIER et al, 1998; 
NIKAIDO, 2001).  Two of the strategies that have been used to overcome this situation is the 
improvement of old antibiotics and the design of new generations of antibiotics, with the help of 
new tools, e.g., bacterial genomics (NIKAIDO, 2001).  
2.2 Mode of action of antibiotics 
Most of the antimicrobials used for the treatment of bacterial infections can be categorized 
according to their principal mode of action: 1) interference with cell wall synthesis, 2) inhibition of 
protein synthesis, 3) interference with nucleic acid synthesis, 4) inhibition of a metabolic pathway 
and 5) disruption of the bacterial membrane structure (TENOVER, 2006).  Table 1 presents some 













Table 1: Mode of action of antibiotics (TENOVER, 2006) 
Mode of action Examples 
 
Interference with cell wall synthesis 
 
β-Lactams: penicillins, cephalosporins, 
carbapenems, monobactams 
Glycopeptides: vancomycin, teicoplanin 
Protein synthesis inhibition macrolides1, cloramphenicol1, clindamycin1, 
linezolid1, aminoglycosides2, tetracyclines2, mupirocin3 
Interference with nucleic acid synthesis fluoroquinolones4, rifampin5 
Inhibition of a metabolic pathway sulfonamides, folic acid analogues 
Disruption of bacterial membrane  
structure 
Polymyxins, daptomycin 
1bind to 50S ribosomal subunit, 2bind to 30S ribosomal subunit, 3bind to bacterial isoleucyl-transfer RNA synthetase,  
4inhibit DNA synthesis, 5inhibit RNA synthesis  
2.3 Antibiotic resistance: emerging problems 
WHO defines antimicrobial resistance as the use of an antimicrobial, in any dose and over any time 
period that causes a selective pressure on microbial populations. Antimicrobials become thus less 
effective against resistant microorganisms that can spread (WHO). 
Selective pressure, which is the driving force of evolution and natural selection caused by the 
prolonged use of antibiotics, had big consequences on the increase of resistance (HAWKEY, 2008a; 
FALAGAS & BLIZIOTIS, 2007). This contributed to unveil strains of bacteria that are no longer 
susceptible to the conventional antimicrobial therapy. In particular, staphylococci, enterococci, 
Klebsiella pneumoniae and Pseudomonas ssp, that are becoming commonplace in healthcare 
institutions. 
Concerning the so called “Dawn of the post-antibiotic era” (FALAGAS & BLIZIOTIS, 2007) there 
are an ongoing international debate regarding the terms multidrug resistance (MDR), extensive 
drug-resistance (XDR) and pandrug-resistance (PDR). Experts from the European Centre for 
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Disease Prevention and Control (ECDC) and the Center for Disease Control and Prevention (CDC) 
met to discuss these terms. It was then proposed that MDR is defined as non-susceptible to at least 
one agent in three or more antimicrobial categories.  XDR is defined as non-susceptible to at least 
one agent in all but two or fewer antimicrobial categories, i.e. bacterial isolates remain susceptible 
to only one or two categories. PDR is defined as non-susceptible to all agents in all antimicrobial 
categories (MGIORAKOS et al, 2008). 
 Regarding the worldwide migration of the populations, control of these infections is also ever more 
difficult, not just in health care institutions, but also, for example, in children attending day care 
centers (HAWKEY & JONES, 2009).  
2.3.1 Types of antibiotic resistance 
Bacteria develop resistance to antimicrobials through a variety of resistance mechanisms that fall in 
three major categories: 1) antimicrobial target and receptor alteration, 2) antimicrobial modification 
or destruction and 3) prevention of the antimicrobial from reaching its intended target by either a 
decrease of permeability due to the LPS or the decrease of porins present in the OM (restricted to 
Gram-negatives) or overexpression of EPs that extrude the antimicrobial (VIVEIROS et al, 2010).  
These mechanisms can be intrinsic or acquired. 
 Innately resistant bacteria: Some species of bacteria, as an intrinsic property, have inherent 
resistance to two or more different classes of antibiotics. They are, thus likewise resistant to all 
members of those antibacterial classes. Intrinsic resistance is conferred mostly by drug 
impermeability through the cell wall. E.g. P. aeruginosa has intrinsic resistance to structurally 
unrelated antimicrobial agents and enterococci are resistant to cephalosporins (TENOVER, 2006; 
STRATEVA & YORDANOV, 2009). 
 Acquired resistance bacteria: Initially, susceptible bacteria become resistant to an antibacterial 
agent, under the selective pressure of the prolonged use of that agent (MACPHERSON et al, 2009). 
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This can be the result of spontaneous mutations – vertical evolution - in the existing DNA or 
acquisition of foreign DNA that encodes resistance – horizontal evolution. Respectively, it may 
occur in the chromosomal DNA or through transformation, conjugation or transduction (THOMAS 
& NIELSEN, 2005). The above-mentioned two types of acquired resistance give bacteria an 
extremely high genetic flexibility (SYKES, 2010). 
Horizontal evolution is the main mechanism through which bacteria evolve into resistant organisms 
(HAWKEY, 2008a; SYKES, 2010; HAWKEY & JONES, 2009; HAWKEY, 2008b). Each of the 
mechanisms of horizontal evolution, which are conjugation, transduction and transformation, can 
introduce DNA with little or no homology with those of the recipient cell. These external DNA is 
obtained with the help of three major entities: plasmids, transposons and integrons.  
Plasmids, which are linear or circular DNA molecules, found in both prokaryotes and eukaryotes 
are capable of autonomous replication. They can self-transfer between strains and species forming a 
mosaic-like structure with different resistant genes (HAWKEY, 2008b). Transposons are mobile 
DNA sequences that can migrate to different regions of the genome of bacteria or even to plasmids. 
There are two types of transposons. The Class I mobile elements or retrotransposons that are first 
transcribed to RNA and then again to DNA by reverse transcriptase enzyme; The Class II mobile 
elements, encode an enzyme called transposase, which regulates transposition (STRACHAN & 
READ, 2004). Integrons that are found in chromosomal DNA, plasmids and transposons have 
pieces of DNA called gene cassettes, which can be incorporated and expressed (SYKES, 2010; 






Mechanisms of resistance 
The most typical mechanisms of resistance are:  
• Mutational alteration of the target protein: bacteria can become resistant through mutations 
that turn the target protein less susceptible to an agent. E.g. fluoroquinolone resistance is 
often due to alteration in the targets, i.e. DNA topoisomerases (NIKAIDO, 2009); 
• Enzymatic inactivation of the drug: secretion of enzymes that degrade the drug are common 
against antibiotics of natural origin, e.g. through enzymatic phosphorylation, and against β-
lactams, which are inactivated by β-lactamases (NIKAIDO, 2009); 
• Acquisition of genes for less susceptible target proteins from other species: the production of 
mosaic proteins give bacteria more possibilities to avoid the noxious effect of antibiotics, 
e.g. penicillin resistance in Streptococcus pneumoniae is related to the production of mosaic 
proteins that in part came from other species (NIKAIDO, 2009);  
• Prevention of drug access to targets: Drug access to a target can be reduced by an active 
efflux pump activity, e.g. Tet (K) encoded protein in S. aureus, or can be reduced locally. 
Local inhibition can be due, for example, to the action of Tet (M) and Tet (S) that by 
changing the ribosomal conformation can prevent the association of tetracyclines to 
ribosomes (ROBERTS, 2005). Another mean of preventing drug access to its target is the 
non-specific inhibition of drug access. Through decreased outer membrane permeability 
(only on Gram-negative bacteria), antibiotics cannot enter bacterial cells, e.g. Enterobacter 





3. Absorption, Distribution, Metabolization and Excretion (ADME) system and transport 
mechanisms  
Membrane transporters perform important functions for the cell such as providing nutrients, 
protecting the cell against noxious agents and establishing electrochemical gradients across 
membranes (ECKER & CHIBA, 2010).  
The ADME kinetics of the organism, describes the disposition of a pharmaceutical compound 
within the organism, influencing thus the drug level and kinetics of drug exposure to the tissues. It 
is applicable to the pharmacokinetics and metabolism investigations in humans and animals, being 
thus critical in all phases of a fully integrated drug development program (www.netsci.org).  
Efflux pumps are determinants for the absorption, distribution and excretion of drugs, toxic 
compounds and their metabolites (VAN BAMBEKE et al, 2000; HULS et al, 2009).  During 
evolution, transport pathways emerged, allowing molecules, such as nutrients and metabolites, to 
cross cell membranes. As a result, the transport of small molecules is mediated by transmembrane 
proteins (ECKER & CHIBA, 2010). Numerous disorders caused by mutations in transporter genes 
underscore the physiological role of efflux pumps, such as Dubin-Johnson syndrome, 
sitosterolemia, or Tangier disease (ECKER & CHIBA, 2010).	  	  
4. Permeability barriers as bacterial defense systems  
In order to survive, bacteria evolved a complex cell wall. This structure protects them against the 
exterior and permits the entrance of nutrients and extrusion of waste products (SILHAVY et al, 
2010).  
The first barrier to antibiotics in bacterial cells is the cell wall, which provides strength, rigidity and 
shape (VIVEIROS et al, 2007). The balance of membrane permeability is of great importance to 
bacteria because it limits the intracellular concentration of antibiotics (NIKAIDO, 2001).  
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4.1 Difference between Gram-positive and Gram-negative bacteria 
Gram-negative cell wall: 
In general, Gram-negative bacteria are more resistant to antibiotics because of the more complex 
architecture of their cell envelope, which includes an outer and inner membrane with the 
periplasmic space in between (SILHAVY et al, 2010) (Figure 1).  
The outer membrane (OM) is a distinguishing feature of Gram-negative bacteria, because Gram-
positives lack this structure. OM gives an additional protection from the environment by excluding 
toxic molecules and providing an additional stabilizing layer.  It is a lipid bilayer that contains 
glycoplipids, mainly lipopolysaccharide (LPS). LPS is a virulence factor that typically consists of a 
hydrophobic domain known as lipid A or endotoxin, a non-repeating core oligosaccharide and a 
distal polysaccharide or O-antigen. The lipid A of LPS is responsible for the septic shock related to 
septicaemia, caused by these microorganisms (SILHAVY et al, 2010).  
The outer membrane proteins (OMPs) of Gram-negatives are divided into two classes: lipoproteins 
and β-barrel proteins. The majority of the OMPs are transmembrane proteins. For example, OmpF 
is a transmembrane protein called porin that allows the passive diffusion of small molecules 
(SILHAVY et al, 2010). 
As demonstrated in Figure 1, the periplasmic space is delimited by the OM and the inner membrane 
(IM). This structure gives Gram-negative bacteria a great evolutionary advantage because it entraps, 
for example, the potentially harmful molecules, such as degradative enzymes. In contrast to the 
Gram-positives, which lack this narrow space, Gram-negatives can pick toxic compounds here and 
expel them directly to the external medium through efflux pumps (represented by the vertical bold 
arrows in Figure 1), strongly reducing the number of molecules reaching their cytoplasmic targets. 
Within the periplasmic space there is the peptidoglycan whose main function is to give rigidity and 
shape to the cell wall. Peptidoglycan is made up of repeating units of the disaccharide N-acetyl 
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glucosamine –N-acetyl muramic acid which is cross-linked by pentapetide side chains. The amount 
of this molecule in Gram-negatives is much lower compared to Gram-positive bacteria (NIKAIDO, 
2001; SILHAVY et al, 2010). 
As widely known, bacteria do not have various organelles, that eukaryotic cells contain. These 
organelles perform a myriad of very important tasks to the cell wellbeing. In bacteria, all these 
“household tasks”, like energy production, protein or lipid synthesis are performed in IM that is a 
phospholypid bilayer. Protein channels involved in the efflux mechanisms are also part of the 
bacterial cell envelope. Within the five superfamilies of transporters (chapter 5), MFS and RND are 
the most abundant. RND transporters (Figure 4), which are found so far exclusively in Gram-
















Gram-positive cell wall: 
Gram-positives lack the OM, which is present in Gram-negatives; the peptidoglycan layer is thicker 
in Gram-positive bacteria, as shown by Figure 2. Interspersed in this layer, there are numerous 
polymers, called teichoic acids (TAs). This polymers account for 60 % of the mass of Gram-
positives envelope, being thus major contributors to cell envelope structure and function 
(SILHAVY et al, 2010). 
In addition to the TAs, there are proteins attached to the surfaces of Gram-positives. Some of 
these proteins have similar properties to those found in Gram-negative periplasmic space, 
furthermore the adhesion to extracellular noxious molecules is a task performed by these 
proteins (SILHAVY et al, 2010). 
Because of their less complex cell envelope, Gram-positives, are considered much more 
susceptible to certain antimicrobials than Gram-negatives, which have been showing greater 













4.2 Transport systems (TENOVER, 2006): 
For most polar molecules, such as nutrients or metabolites, the lipid bilayer (Figure 1) of a cell 
membrane represents an impermeable membrane. The transport of small molecules is mediated by 
transmembrane proteins, whereas macromolecules and small particles cross membranes by various 
cytotic mechanisms (ECKER & CHIBA, 2010).  
Diffusion is the translocation of molecules from a region of higher concentration to a region of 
lower concentration. This is mediated by pore forming channels. There are also membrane proteins 
that mediate the translocation of molecules that are too polar or too large to move across a 
membrane by diffusion. In contrast to pore forming channel proteins, carrier proteins bind their 
substrates at specific binding sites, resulting in the so called “facilitated diffusion” (ECKER & 
CHIBA, 2010). There are three types of membrane transporter proteins (ECKER & CHIBA, 2010) 
(Figure 3):  
• Uniport, when the carriers mediate transport of a single substrate;  
• Symport, when the carriers bind to different substrates and transport them together across 
the membrane; 
• Antiport refers to those transporters that exchange one substrate for another across the 
membrane. 
The so-called cotransport systems – symporters and antiporters - permit the simultaneous or 
sequential passive transfer of molecules or ions across biological membranes (Figure 3). 
Cotransporters are classified in symporters and antiporters depending on the direction of the second 
substrate. Symport refers to migration of molecules in the same direction, whereas antiport in 
opposite directions.  Bmr and Blt from Bacillus subtilis are examples of antiporters (LI & 
NIKAIDO, 2009) whereas E.coli LacY functions as a symporter (GUAN & KABACK, 2006). 
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In contrast with the facilitated diffusion, active transport systems couple the transport with energy. 
There are two types of active transport. In primary active transport the energy comes from the ATP 
hydrolysis, whereas in the secondary active transport the energy is provided by the flow of ions, 







5. Families of transporters 
Efflux pump systems are present in all living systems, providing a frontline nonspecific defense, 
with standard responses to the external stimuli (RICE, 2007). 
Substrate specific transporters constitute systems that are responsible for the extrusion of a given 
drug or class of drugs. On the contrary, the multidrug transporters are capable to handle a wide 
variety of structurally unrelated compounds. MDR transporters can be divided in two groups based 
on their structure and bioenergetics: 1) secondary multidrug transporters, that are predominant in 
bacteria, use the transmembrane electrochemical gradient of protons or sodium ions to extrude the 
drugs from the cell. Instead, the 2) primary multidrug transporters extrude their substrates with the 
energy of ATP hydrolysis. (ECKER & CHIBA, 2010; BORGES-WALMSLEY et al, 2003). 
Although both primary and secondary transporters (Figure 5) are ubiquitous in bacteria, their 
relative presence seems to correlate with energy generation: fermentative bacteria tend to rely more 
Figure 3 – Schematic representation of uniport, symport and antiport systems  
The arrows represent the direction of transported ions or molecules through the transport 
system.  




on the primary transporters while aerobic bacteria contain somewhat more secondary transporters in 
their genomes (PAULSEN et al, 2000). 
Bacteria appear to be particularly endowed with multidrug resistance transporters. Considering 
predictions from the bioinformatic analysis of more than 200 available bacterial genomes, putative 
MDRs comprise 2 to 7 % of the total bacterial protein complement (SAIER & PAULSEN, 2001). 
Among these bacterial genomes, not all have been confirmed to be polyspecific, but quite a few of 
them are, underscoring the impressive resistance capacity of bacteria.  
Functional studies and subsequent phylogenetic analysis demonstrated that bacterial MDR 
transporters could be organized into five evolutionary distinct protein superfamilies that 
significantly differ in bioenergetics, structure and transport mechanism (SAIER & PAULSEN, 
2001). This structural and functional diversity gives bacteria a big potential to combat noxious 
agents (SAIER et al, 1998 ). 
5.1 Primary multidrug transporters in bacteria: 
5.1.1 ABC transporters in bacteria: 
In bacteria, these transporters are predominantly involved in the import of essential compounds that 
cannot be obtained by diffusion (sugars, vitamins, metal ions and others). In spite of the importance 
of these transporters in eukaryotic cells, in bacteria their role is more limited. However, both 
antibiotic-specific and polyspecific ABC transporters have been identified (ECKER & CHIBA, 
2010; NIKAIDO, 2009).  
The most well-studied bacterial ABC multidrug transporters are LmrA and LmrCD, both from 
Lactococcus lactis (ECKER & CHIBA, 2010). LmrA is homologous to one half of the mammalian 
MDR1 (NIKAIDO, 2009; PUTMAN et al, 2000). Instead of the minor role played by LmrA in L. 
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lactis, its overproduction in E. coli confers resistance to cationic dyes, daunomycin and 
triphenylphosphonium (NIKAIDO, 2009). 
The data available suggests that ABC transporters are more present in Gram-positive bacteria 
(ECKER & CHIBA, 2010). Another example of this superfamily of transporters is S. aureus 
Sav1866 that is homologue to LmrA (NIKAIDO, 2009; LI & NIKAIDO, 2009). 
 
5.2 Secondary multidrug transporters 
The majority of the multidrug efflux systems known to date are sensitive to agents that dissipate the 
proton motive force (PMF). Thus, these transporters couple the extrusion of drugs and other toxic 
agents with the exchange of protons or sodium ions. Related to their size and structures, secondary 
transporters can be subdivided into distinct superfamilies: the major facilitator superfamily (MFS), 
the small multidrug resistance (SMR) superfamily, the resistance-nodulation-cell division (RND) 
superfamily and the multidrug and toxic compound extrusion (MATE) superfamily (ECKER & 
CHIBA, 2010).  
5.2.1 Major facilitator superfamily (MFS) 
The MFS is the largest characterized superfamily of transporters (LI & NIKAIDO, 2009; FLUMAN 
& BIBI, 2009). These transporters are found in all living organisms and are implicated in the 
symport, antiport or uniport of various substrates, such as sugars, drugs, neurotransmitters or amino 
acids (FLUMAN & BIBI, 2009). This superfamily contains transporters that extrude one specific 
substrate and transporters that extrude a variety of them. Based on phylogenetic analysis, it appears 
that specific and MDR transporters in the MFS appeared randomly on the evolutionary tree, 
indicating that the broadening and narrowing of specificity toward particular drugs occurred 
repeatedly during evolution. For example, a single amino acid change in the S. aureus QacB 
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transporter enables it to recognize not only monovalent but also divalent cationic compounds 
(PAULSEN et al, 1996). In addition, mutations that alter the substrate specificity of the transporters 
are thus of great importance as though, usually influence the transport of a subset of substrates.  
Therefore, these mutations usually occur in residues that participate in substrate binding. For 
example, Bmr, found in Bacillus subtilis, is one of the MFS transporters that harbor some of these 
residues, typically found inside of transmembrane domains (TMDs). Some of the substrate binding 
sites in this family are very large, thus with the ability to bind more than one substrates 
simultaneously (FLUMAN & BIBI, 2009).   
These proteins can be clustered into two different groups, with either twelve or fourteen 
transmembrane segments (TMS). It has been proposed to function by an alternating access, rocker 
switch- type- structural mechanism, in which the substrate binding site is alternatively accessible 
from both sides of the membrane. For example, the EmrB of E. coli, where the MFS systems can 
function as components of tripartite systems (LI & NIKAIDO, 2009). 
Other examples:  NorA was first discovered in S. aureus and is from the 12-TMS cluster. It confers 
resistance to hydrophilic compounds and none to hydrophobic ones (FLUMAN & BIBI, 2009). 
Bmr, from B. subtilis, is structural and functionally homolog to NorA (AHMED et al 1995).  
 
5.2.2 Small multidrug resistance superfamily (SMR) 
The SMR superfamily, most found in Eubacteria (BAY et al, 2008), is the smallest secondary MDR 
transporter known, composed of around 100 amino acids. SMR transporters are believed to span the 
cytoplasmic membrane as four transmembrane (TM) α-helices with short hydrophilic loops, thus 
making them highly hydrophobic. 
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Members of this superfamily have been identified, encoded by a variety of plasmids and 
transposable members giving high resistance to a wide range of antibiotics. E.g. QacH in 
Staphylococcus saprophyticus. (PUTMAN et al, 2000).  
Among Gram-negative bacteria, EmrE from E. coli, is considered the structural archetype of all 
SMR proteins (SCHULDINER et al, 2001). The scientific data available reveals that these 
transporters function as an oligomer, most likely a dimer. There are other examples, like the Mmr of 
Mycobacteria tuberculosis that confers resistance to ethidium bromide, erythromycin, or the 
antiseptic resistance multidrug transporter QacE present in Klebsiella aerogenes (PUTMAN et al, 
2000). 
 
5.2.3 Resistance-Nodulation-Cell Division Superfamily 
The RND transporters (Figure 4 and Figure 5) are responsible for the high intrinsic antibiotic 
resistance found in Gram-negative bacteria (MURAKAMI, 2008). They are also found in Gram-
positive bacteria as well as in M. tuberculosis where one of these RND type pumps is responsible 
for the efflux of the first-line antimycobacterial drug, isonazide (PASCA et al, 2005).  These 
transporters are composed of approximately 1000 amino acid residues, adopting a 12-helical 
structure, comprising large periplasmic or extracytoplasmic domains between helices 1 and 2 and 
between helices 7 and 8. 
RND transporters contain an astonishing wide range of substrate specificity surpassing even the 
ABC transporters (ZGURSKAYA & NIKAIDO, 2002). These pumps require three units: a 
transporter protein in the IM, called AcrB, in association with two more classes of proteins, such as 
the OMF (outer membrane factor) Tol C and the MFP (membrane fusion protein) AcrA from E. coli 
(Figure 4) (MURAKAMI, 2008). These transporters are very complex because without one of the 
three parts available, the complex turns non-functional.  
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It was shown that by inactivating the AcrB, bacteria become susceptible to some drugs (LI & 
NIKAIDO, 2009). Based on former results it can be supposed that the periplasmic loops of RND 
transporters are critical in substrate determination, possibly containing multiple binding sites for 







5.2.4 Multidrug and Toxic Compound Extrusion Superfamily (MATE) 
There are twenty MATE transporters characterized to date. Most members of this family consist of 
400-500-residue polypeptides with 12 putative transmembrane helices (TMHs) (LI & NIKAIDO, 
2009). Phylogenetic analyses classify these transporters into three subfamilies. Little is known 
about the molecular mechanism underlying their organic cation transport. However, there are some 
similarities with the MFS superfamily (LI & NIKAIDO, 2009; MCALEESE et al, 2005). 
Examples: NorM from Vibrio parahaemolyticus and MepA from S. aureus are both MATE 
transporters implicated in the resistance to antibiotics, conferring resistance to fluoriquinolones and 
tigecycline, respectively (LI & NIKAIDO, 2009; MCALEESE et al, 2005).  
Figure 4 – Schematic representation of the RND superfamily: the structure of AcrAB-Tol 
C (POS, 2009). 
The tripartite complex is represented by the different colours:  in blue, the inner membrane 















Figure 5 – Schematic representation of the five superfamilies of multidrug transporters. 
The ATP-binding cassette (ABC) superfamily is the only one belonging to the primary multidrug transporters. The 
other four superfamilies belong to the secondary multidrug transporters. 
Source: www.nature.com  
21	  
	  
6 – Multidrug resistance in cancer 
Cancer is one of the most fatal diseases worldwide (WHO). In poor and developed nations, cancer 
is a leading cause of death. 70 % of all cancer deaths occurred in middle and low-income countries. 
The WHO projections for 2030 are around 11.5 million deaths. Limited improvement in diagnosis, 
surgical techniques, patient care and adjuvant therapies are among the top causes of this projection 
(FIEDLER, 2002) 
6.1 Cancer burden 
In Europe, 3.2 million people are diagnosed with cancer every year (FERLAY et al, 2010). In both 
sexes, in EU, cancers with the higher rates of incidence are: prostate cancer, breast cancer, 














There are also differences in the incidence between men and women. In men the types of cancer 
with higher mortality rate are: prostate cancer, lung cancer, and colorectal cancer. In women, the 
most common types of cancer are breast cancer, colorectal cancer and lung cancer (FERLAY et al, 
2010). 
6.2 Causes of cancer 
The transformation from a normal cell into a cancer one is a multistage process that begins from 
one single cell (STEVENS & LOWE, 2000; LUO & ELLEDGE, 2008). These changes can be due 
to genetic factors, ageing and three categories of external agents (www.cancer.org) such as:  
• Physical carcinogens (e.g UV light); 
• Chemical carcinogens (e.g tobacco smoke); 
• Biological carcinogens (e.g HPV virus). 
 
7. Relationship between bacterial infection and cancer 
Bacterial infections can also be risk factors for cancer development, for instance Helicobacter 
pylori and Salmonella typhi can be involved in cancer development. H. pylori infects, at least 50 % 
of worldwide population. Within other malignancies, such as chronic inflammation or peptic ulcer 
disease, it is a risk factor for gastric cancer and mucosa-associated lymphoid tissue (MALT) 
lymphoma. In order to combat H. pylori an initial treatment has been developed consisting of a 
triple therapy that contains a proton pump-inhibitor (PPI). The treatment consists of clarithromycin, 
metronidazole or amoxicillin with a PPI, such as esomeprazole (BERGMAN & D’ELIOS, 2010; 
FISCHBACH et al, 2009). Resistance to clarithromycin has yet been reported in various countries 
(FISCHBACH et al, 2009). 
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Chronic infection with S. typhi can be related to gallbladder cancer. Carriers of this pathogen have 
an eight-fold higher risk of developing this type of cancer than non-carriers. The exact pathogenesis 
is yet to be understood but there is increasing evidence that the products of the degradation of bile-
salts may contribute to tumorogenesis (SAMARAS et al, 2010). 
8. Carcinogenesis - the development of cancer  
In the human body, cells grow and divide in a controlled fashion to produce more cells, in order to 
keep the body healthy.  Certain stimuli cause changes in genetic material that result in permanent 
alteration of the normal cellular growth pattern (STEVENS & LOWE, 2000). These distorted cells 
fail to respond normally to signals controlling cell growth; they are termed neoplastic (STEVENS & 
LOWE, 2000), because they proliferate uncontrolled, forming a tissue called neoplasm, which 
means “new growth”.  
As shown by Figure 7, there is a difference between the normal and cancer cell division. Apoptosis 
or programmed cell death is a normal component of the development and health of multicellular 
organisms. Through apoptosis cells die in a controlled and regulated manner.  
The main reason for the difficulties in cancer therapy is that cancer cells can spread to other organs. 
This process is called metastasis and refers to the growing of a secondary tumor that was originated 
from a primitive neoplasm (GUPTA & MASSAGUE, 2006). 
As seen in Figure 8, the invasive cancer cells migrate from the primary tumour site into the 
surrounding tissue through blood vessels. Cells are thus carried to distant organs where they lodge 
in their small capillaries. They form secondary tumours by extravasating to the surrounding tissue 
(STEVENS & LOWE, 2000). As neoplastic cells are continually growing, they need an appropriate 
set of support tissues, particularly an adequate set of vascular supply that is why angiogenesis is 













9. Cancer therapy and the problem of resistance mechanisms to anticancer agents 
Chemotherapy is the treatment of choice for ~50 % of all types of cancer (AMBUDKAR et al, 
2005), the effectiveness of chemotherapy – a cancer treatment that uses drugs to destroy cancer 
cells - is of big concern for medicine. Combination chemotherapy is the use of different chemical 
agents simultaneously. It was first introduced in 1963 for the treatment of resistant cancers (SHEPS 
& LING, 2007).  
9.1. Main groups of anticancer drugs 
Among the great amount of cells that forms a neoplasm, not all are in the same development stage 
or respond in the same way to the same stimulus. In order to prevent selection of resistant cancer 
Figure 7.  Cellular division in normal and cancer cells.  
A – Normal cell division; B – Cancer cell division;  
 Source: http://www.jyi.org  
A 
B 
Figure 8. Schematic representation of the metastasizing process. 
1 – Attachment of the tumour cells; 2 – Influx of tumour cells through a  
vessel breakdown; 3 – Locomotion of the tumour cells through the  
circulatory system; 4 – Adhesion of the tumour cell mass in a different 
body location.  




cells, contemporary chemotherapy uses combinations of various drugs of different targets. There are 
five main families of anticancer drugs: 
• Alkylating agents: drugs that bind to the DNA, e.g. cisplatin, ifosfamide 
(STAVROVSKAYA, 2000; TASCILAR et al, 2007); 
• Anticancer antibiotics: These agents act by topoisomerase inhibition, e.g. daunorubicin, 
doxorubicin (STAVROVSKAYA, 2000; KURUVILLA, 2009 ); 
• Antimitotic agents: Depolymerization of microtubules and damage to mitotic spindle, e.g. 
vinca alkaloids and taxanes (STAVROVSKAYA, 2000; PEREZ, 2009); 
• Antimetabolites: The main mechanism of action of these agents is the inhibition of 
enzymes participating in DNA or RNA synthesis, e.g. methotrexate, gemcitabine 
(STAVROVSKAYA, 2000; MERL et al, 2010).  
• Hormones: Hormones can be a natural product of an organ or represent abnormal synthesis 
reflecting unregulated cancer cell metabolism. Drugs, such as tamoxifen are antagonists of 
the estrogen receptor, obstructing the effect of the hormones (JORDAN, 2006). 
9.2. Resistance to anticancer agents: 
In order to resist to the effects of anticancer drugs, tumour cells have various ways to resist their 
noxious effects. There are thus four main mechanisms of drug resistance: 
• Decrease of drug accumulation by the cells: drugs inside the cells can be extruded due to 
the activation of transporter proteins. Otherwise, these drugs remain inside the cells, able to 
exert their toxic effect. E.g. P-gp. (STAVROVSKAYA, 2000; LAPENSEE & BEN-
JONATHAN, 2010 ).  
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• Detoxification of the drug in the cell: Cells have mechanisms to turn drugs ineffective. 
One of these mechanisms is the cellular glutathione system (CGS). Glutathione forms a 
conjugate with the reactive site of the drug that is more water-soluble and less active. This 
conjugate is then extruded from the cell through transporter proteins, such as GS-X 
(including MRP) (STAVROVSKAYA, 2000; MOSKAUG et al, 2005 ). 
• Alteration of drug targets: Gene mutations are common in cancer cells that often render 
drug targets unrecognizable. Sometimes, during the progression of cancer, some targets are 
lost, for example the estrogen receptor in the progression of breast cancer. Another way of 
drug target alteration is the increase of target proteins, which is caused by the over-
expression of the gene that controls the target molecule (STAVROVSKAYA, 2000; LO & 
SUKUMAR, 2008). 
• Key genes that control apoptosis: One of these genes is p53, also known as “guardian of 
the genome”. p53 is often altered in tumour cells, resulting in impaired function and 
inducing apoptosis (STRACHAN & READ, 2004; STAVROVSKAYA, 2000; BELL & 
RYAN, 2007 ). 
10. The importance of ABC transporters in cancer 
Multidrug resistance is a major obstacle to the success of cancer chemotherapy. It is mainly related 
to the expression of ABC transporters (HALL et al, 2009). Forty-nine members of this superfamily 
have already been identified and classified in seven subfamilies based on their phylogenetic 
similarity (KLEIN et al, 1999). 
P-glycoprotein (P-gp), the product of MDR-1 (ABCB1) gene, was the first to be discovered and is 
the most known efflux pump within ABC transporters (HALL et al, 2009). ABCB1 is found in 




10.1 Physiological localization of ABCB1 (P-glycoprotein) 
As seen in Figure 9, ABCB1 is expressed in the lumen of the endothelial cells, which comprises the 
blood-brain barrier. It is found in the canalicular membrane of hepatocytes, brush-border membrane 
of proximal tubules in the kidney, mediating thus the expression into the urine. ABCB1 also 
prevents the absorption of substrates into the human body because it is present in the intestine 
















In humans, defective ABC transporters are associated with several diseases, including Dubin-
Johnson syndrome, sisterolemia and Tangier disease (ECKER & CHIBA, 2010). ABC transporters 
are often responsible for clinical MDR; consequently these transporters are also often a sign of poor 
Figure 9.  Physiological distribution of ABCB1 (P-
glycoprotein) (HULS et al, 2009). 
Representation of the various organs where ABCB1 has a 
normal physiological role. 
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prognosis (STAVROVSKAYA & STROMSKAYA, 2008). Mutations in genes encoding ABC 
transporters can induce a multitude of defects, presenting as autosomal recessive conditions. A good 
example is the cystic fibrosis transmembrane regulator protein (CFTR), a member of the ABCC 
subfamily. A mutation in the encoding gene on chromosome 7 impairs the synthesis of CFTR 
resulting in cystic fibrosis (LEONARD et al, 2003). 
Like MRP1 – the second drug transporter in humans (COLE et al, 1993) – ABCB1 is thought to 
provide protection to normal tissues, preventing the accumulation of or exposure to toxic substances 
(HOLLAND et al, 2003; LEONARD et al, 2003). Mice lacking ABCB1 homologue (mdr1a and 
mdr1b) have a subtle phenotype indicating a role for ABCB1 in the physiological defense against 
xenotoxins (SCHINKEL, 1997). 
10.2 Structure of ABC transporters 
In contrast to prokaryotes, in eukaryotes the major mechanism of efflux is dependent on proteins 
that derive their transport energy from the hydrolysis of ATP. The majority of these transporters 
belong to the ABC superfamily (BORGES-WALMSLEY et al, 2003), such as ABCB1 (also known 
as P-gp), ABCC1 [also known as multi-drug resistance-associated protein (MRP1)] or ABCG2 
[also known as breast cancer-resistance protein (BCRP)] (LIU, 2009). 
The members of this superfamily translocate a wide range of substances (including sugars, amino 
acids, sterols, peptides, antibiotics, xenobiotics between others) across cytoplasmic and organellar 
membranes (LEONARD et al, 2003).  
In eukaryotes, molecules are mostly transported from the cytoplasm to the outside of the cell or into 
an intracellular compartment (endoplasmic reticulum, mitochondria, peroxisome) (DEAN et al, 
2001). 
The topology of these transporters indicates the existence of highly hydrophobic transmembrane 
domains (TMDs) with between 4 and 10 TM α-helices – typically six per domain - and hydrophilic 
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cytosolic ATP binding/hydrolysis domains, the so called nucleotide binding domains (NBDs). The 
minimal structural requirement for an active eukaryotic ABC transporter is thought to consist of two 
TMDs and NBDs each (Figure 10) (LIU, 2009; TUSNÁDI et al, 1997). 
All ABC proteins, in prokaryots and eukaryotes, have two cytoplasmic nucleotide binding domains 
containing conserved sequence motifs for binding/hydrolysis of ATP (LOCHER & BORTHS, 
2004). In eukaryotes, the NBD’s contribution to the protein activity is often non-equivalent – 
deletion of either NBD abolishes transport (JHA et al, 2003) - whereas in some prokaryotes both 
are functionally identical. The primary structures of NBD’s show ~25% sequence identity across 
the whole superfamily (KERR, 2002). Marked sequence conservation is observed over three short 
regions found in NBDs: the Walker A and Walker B regions, which are separated by approximately 












Figure 10. Schematic representation of the organization of the P-glycoprotein. 
In this 2-D model of P-gp each circle represents an amino acid residue, the blue circles represent mutations that 
alter substrate specificity, and the red circles represent phosporylation sites. The Walker A, B regions and the 
signature motif or C region are circled.  
Adapted from Reference AMBUDKAR et al, 2003.  
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10.2.1 Structure of ABCB1 
ABCB1 comprises 12 transmembrane segments divided into two TM domains, each linked with an 
ATP-binding domain (Figure 10). 
When a substrate approaches the ABCB1, it binds to the high affinity binding domain, promoting 
the ATP hydrolysis, resulting in a conformational change that shifts the substrate to a lower affinity 
binding site, releasing it into the extracellular space or outer leaflet of the membrane. ABCB1 is 
able to bind substrates again after ATP hydrolysis at the second binding site (LEONARD et al, 
2003). 
   
11. Efflux pump inhibitors 
11.1 Efflux pump inhibitors in bacteria 
The use of efflux pumps inhibitors (EPIs) has been investigated in order to improve and potentiate 
the activity of antibiotics. The goal has been the development of compounds that decrease the level 
of intrinsic resistance, significantly reverse acquired resistance, and promote the decrease of the 
frequency of emergence of multidrug resistant bacteria (LOMOVSKAYA et al, 2001). One such 
example is the EPI carbonyl cyanide m-chlorophenylhydrazone (CCCP) that promoted the 
inhibition of EB in E.coli AG 100TET (E.coli with overexpressed AcrAB efflux pump) as shown by 
Martins et al (MARTINS et al, 2009). Various EPIs may be the substrates for the pumps that they 
inhibit (LI & NIKAIDO, 2009). Representative efflux pumps such as the E. coli AcrAB-TolC have 
been used to screen and characterize possible EPIs. Thus, one of the most critical issues in the quest 
for new EPIs is the understanding of how EPIs block the transport of drugs out of the cell, as shown 




















Concerning the fact that one single bacterium has various efflux pumps conferring resistance to 
various antibiotics, it seems obvious to develop broad-spectrum inhibitors, capable to interact with 
various efflux pumps (POOLE, 2007). Pagès et al resumed the possible targets of bacterial 
inhibitors, such as collapsing energy used by efflux pumps, inhibiting their functional assembly or 
the blockage of the outer membrane channel (PÀGES & AMARAL, 2009). 
   
EPIs Gram-negative bacteria 





Secondary transporters Multiple antibacterials 
Arylpiperazines: 1-(1-
naphthylmethyl)-
piperazine and others 
RND pumps of A. 
baumannii, Citrobacter 
freundii, E. aerogenes, E. 




Quinoline derivatives AcrAB-TolC of E. 
aerogenes, E. coli, K. 
pneumoniae 
Multiple antibacterials 
Extracts of Berberis 
aetnensis 
E. coli, P. aeruginosa, S. 
aureus 
Ciprofloxacin 
EPIs Gram-positive bacteria 
Fluoroquinolone 
derivatives 
MepA and NorA 
of S. aureus 
Fluoroquiniolones 
GG918 (synthetic) S. aureus Fluoroquinolones 
Reserpine Bmr of B. subtilis, 
EfrAB of E. faecalis, 
NorA and Tet(K) of 
S. aureus, PmrA and 
PatAB of S. 
pneuomoniae 
Fluoroquinolones and tetracyclines 
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11.2 Efflux pump inhibitors in eukaryotes 
ABCB1 demonstrates high transport capacity and a wide range of substrate specificity. In general 
these transported molecules are hydrophobic and amphipathic, uncharged or basic, although 
negatively charged molecules can also be transported (COLE et al, 1992). 
The most common approach to interfere with overexpressed ABCB1 activity is the use of inhibitors 
(YANG et al, 2008). Until now three generations of ABCB1 inhibitors have been identified and 
developed. Some ABCB1 substrates and inhibitors are demonstrated by Table 3.  
Table 3. ABCB1 substrates and inhibitors (MARCHETTI et al, 2007; LEONARD et al, 2003 ). 
ABCB1 substrates ABCB1 inhibitors 
Adriamycin Verapamil 






Etoposide Zosuquidar trihydrochloride 
Mitoxantrone Biricodar 
Actinomycin D Elacridar 
 
It has been established that ABCB1 is capable to interact with more than 200 compounds, that can 
be classified based on the transported substrates and the modulators (DIDZIAPETRIS et al, 2003).  
In cancer cells, ABCB1 is associated with the MDR phenotype, mediating resistance to 
anthracyclines, vinca alkaloids, colchicine, epipodophyllotoxins and paclitaxel (LEONARD et al, 
2003). Thus, the wide spectrum of resistance and the poor prognosis urged the need to circumvent 
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the actions of ABCB1. Broad spectrum inhibitors appeared in the 1980’s and brought a certain 
degree of optimism; these molecules could thus restore some sensitivity to chemotherapy (ECKER 
& CHIBA, 2010). The use of established drugs for the modulation of ABCB1 function formed the 
first generation of inhibitors (TSURUO et al, 1984).  
So far, three generations of compounds have been identified and developed as ABCB1 inhibitors 
that can be also classified as competitive and non-competitive inhibitors. As the name implies, the 
competitive ones fight with the cytotoxic agents for transport. If successful, the cytotoxic agent 
could be transported by the pump, remaining inside the cell. Their non-competitive counterparts do 
not compete for the same target. They bind to another target, in order to change the pump 
conformation, so that the active site is no longer recognized by the substrates (YANG et al, 2008 ). 
 
FIRST GENERATION of inhibitors 
Verapamil and tamoxifen are among the most known ABCB1 modulators that belong to the first 
generation of compounds, which means that, they are not specific for ABCB1. In general they are 
less effective and toxic (MARCHETTI et al, 2007; YANG et al, 2008). 
SECOND GENERATION of inhibitors 
The approach used for the second generation of ABCB1 inhibitors involved the use of chemical 
derivatives of the drugs, in order to improve potency, specificity and ABCB1 binding affinity. They 
are divided in two categories, those that are analogues of the first generation, i.e.dexverapamil 
(WILSON et al, 1995) and those with new chemical structures, i.e. biricodar (YANG et al, 2008 ). 
In comparison with the first generation of inhibitors, inhibitors of the second generation have higher 
ABCB1 inhibitory capacity and less toxic side effects; however they can have unpredictable 
interactions between anticancer drugs (YANG et al, 2008).      
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THIRD GENERATION of inhibitors 
Concerning the strategies used in the third generation of compounds, the goal is to overcome the 
toxicity of the previous generations to improve the pharmacokinetic interactions of the compounds. 
The new tools at disposal, such as computational chemistry or molecular pharmacology, have been 
fundamental for shifting the approach of blind screening to rational drug design. These new tools, 
also with the help of quantitative structure-activity relationship (QSAR) have been very useful for 














12. Hydantoin derivatives and their pharmacological use 
12.1 Physiological and biochemical role of hydantoins 
Hydantoins participate in the purine catabolic pathway that regulates the purine pool in the cell to 
provide precursors for nucleic acid synthesis, hydantoinases, hydantoin transporters (SUZUKI & 
HENDERSON, 2006). 
Hydantoin is a heterocyclic organic compound, the product of glycolic acid and urea, also known as 
glycolyurea. In a more general sense, hydantoins refer to chemical compounds that have substituent 
groups bonded to a hydantoin ring.  
Hydantoin derivatives are famous for their physiological activity as anticonvulsants, which explain 
the continuous research interest on this class of compounds (AHMEDOVA et al, 2009). Epilepsy is 
widely recognized as one of the most known neurological diseases in man. Its most known 
characteristic is the uncontrolled convulsions, the result of excessive temporary neuronal 
discharges. 5,5-diphenylhydantoin, commonly known as phenytoin, is used since 1938, being the 
treatment of choice for generalized tonic-clonic seizure, instead of a high number of side effects 
related (THENMOZHIYAL et al, 2004). 
They are also widely used in numerous pharmacological applications. Thus, many derivatives have 
been identified as anticarcinogenics, antimuscarins, antiulcers, antiarrythmics, antivirals, 
antidiabetics, serotonin and fibrinogen receptor antagonists, inhibitors of the glycine binding site of 
the NMDA receptor and antagonists of leukocyte cell adhesion (OLIMPIERI et al, 2009) and other 
activities including fungicidal and anti-HIV activity (KHANFAR et al, 2009).  
In general, all these activities are possible because of the interaction between the hydantoin ring 
(shown in Figure 11) and the different substituent groups attached to it (OLIMPIERI et al, 2009).  It 
is well established that the type of substituent at 5-position in the hydantoin ring is of crucial 
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importance for the pharmacological action of the corresponding compounds (AHMEDOVA et al, 
2009).  
 
12.2 Structure of hydantoin derivatives 
As summarized by Roszak and Weaver (ROSZAK & WEAVER, 1998) the hydantoin ring can be 
split into two structural fragments responsible for the anticonvulsant activity and for the mutagenic 












Figure 11. Structure of the hydantoin ring and its double activity 
(AHMEDOVA et al, 2009) 
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II - OBJECTIVES OF THE THESIS 
The present work involves the study of primary and secondary efflux pumps, in eukaryotic and 
prokaryotic cells, respectively. In bacteria, the experimental models were Staphylococcus aureus 
ATCC 25923, Enterococcus faecalis ATCC 29212, E. coli AG 100 and Salmonella Enteritidis 
NCTC 13349 strains. In the cancer model, parental mouse T-cell lymphoma cell line and its human 
MDR1(ABCB1)-gene transfected subline were used. 
The main aim of the study is to look for new effective, hydantoin modulators of efflux pumps in 
bacteria and cancer cells to develop new pharmacological agents that reverse multidrug resistance. 
The main goals of the study: 
The biological activity of hydantoin derivatives in bacteria will be demonstrated as follows:    
1. Determination of minimum inhibitory concentrations of the hydantoin derivatives on 
different bacterial strains; 
2. Real-time accumulation of ethidium bromide by different bacterial strains in the presence of 
hydantoin derivatives using real-time fluorometry. 
 
The biological activity of hydantoin compounds in cancer cells will be demonstrated by different 
methods: 
1. The antiproliferative and cytotoxic effect of the compounds will be studied in parental 
(PAR) mouse T-lymphoma cell line and its human MDR1-gene transfected subline (MDR) 




2. Screening of possible effective MDR modulators by real-time fluorometry assessing 






















III – MATERIALS AND METHODS    
1 - Materials 
1.1 Compounds tested  
Thirty hydantoin derivatives (SZ-2, SZ-7, LL-9, BS-1, JH-63, MN-3, TD-7k, GG-5k, P3, P7, 
P10, P11, RW-15b, AD-26, RW-13, AD-29, KF-2, PDPH-3, Mor-1, KK-XV, Thioam-1, JHF-1, 
JHC-2, JHP-1, Fur-2, GL-1, GL-7, GL-14, GL-16, GL-18) were kindly provided by Dr. Jadwiga 
Handzlik and Prof. Dr. Katarzyna Kieć-Kononowicz, Cracow, Poland). The structures are 
confidential. All the compounds were dissolved in DMSO (Merck, Darmstadt, Germany). 
 1.2 Solutions 
Table 4. Used solutions 




Tablet, containing [137 mM NaCl; 2.7 mM KCl; 8 mM 




10 mg/mL in sterile bi-destilled water 
(kept in the dark) 
1 Sigma (St. Louis, MO, USA) 
MTT (Thiazolyl blue tetrazolium bromide) was purchased from Sigma (St. Louis, MO, USA) and a 
stock solution of 5 mg/mL was prepared in PBS. 
SDS (sodium dodecyl sulphate) purchased form Sigma-Aldrich Chemie GmbH (Steinheim, 




1.3 Bacterial strains. 	  
The following bacteria were employed in this study: Salmonella Enteritidis NCTC 13349, wild-type 
Escherichia coli K-12 AG100 (argE3 thi-1 rpsL xyl mtl delta (gal-uvrB)  supE44) (OKUSU et al, 
1996), Staphylococcus aureus ATCC 25923 and Enterococcus faecalis ATCC 29212. E. coli K-12 
AG100 have been previously characterized by Okusu et al (OKUSU et al, 1996).	  
Stocks of bacteria were kept at -80 ºC in liquid media, supplemented with 15% (v/v) glycerol. 	  
1.4 Cell lines.  
L5178Y mouse T-cell lymphoma cells (ECACC cat. no. 87111908, U.S. FDA, Silver Spring, MD, 
USA) were transfected with pHa MDR1/A retrovirus, as described previously (PASTAN et al, 
1988; CHOI et al, 1991). The ABCB1-expressing cell line was selected by culturing the infected 
cells with 60 ng/mL of colchicine (Sigma-Aldrich Chemie GmbH, Steinheim, Germany) to 
maintain the MDR phenotype. L5178 mouse T-cell lymphoma cells (parental, PAR) and the human 
ABCB1-gene transfected sub-line (MDR) were cultured in McCoy's 5A medium supplemented with 
10% heat-inactivated horse serum, L-glutamine (Lonza BioWhittaker) and antibiotics (penicillin, 









1.5 Broths and culture media. 
All the solutions listed in Table 6 were dissolved in distilled water. The solutions were sterilized 
and autoclaved for 15 minutes, at 121 ºC. 
Table 5. Media 
Bacterial culture media Preparation /Composition (per liter) 
 
TSB(1) 
(Tryptic Soy Broth) 
30.0 g of TSB (17 g tryptone, 3 g soytone, 2.5 g di-
potassium hydrogen phosphate, 5 g sodium chloride, pH 
7.3 ± 0.2 at 25 ºC) 
 
TSA 
(Tryptic Soy Agar) 




10 g peptone from casein(3), 5 g yeast extract(3),10 g sodium 
chloride(4), pH 7.0 
MHB(1) 
(Mueller-Hinton Broth) 
21.0 g of MHB (300 g of dehydrated infusion from beef, 
17.5 g casein hydrolysate, 1.5 g starch, 7.3 ± 0.1 at 25ºC) 
MHA(1) 
(Mueller-Hinton agar) 
38.0  g of MHA (300 g of dehydrated infusion from beef, 
17.5 g casein hydrolysate, 1.5 g starch, 17 g agar, 7.3 ± 0.1 
at 25ºC) 
(1) Oxoid Ltd, Basingstoke, Hampshire, England; (2) Scharlau Chemie SA, Barcelona, Spain; (3) Merck, Darmstadt, 
Germany; (4) Panreac Química, Barcelona, Spain. 
1.6 Cell culture media. 
McCoy's 5A medium (Lonza BioWhittaker, Verviers, Belgium) supplemented with 10% heat-
inactivated horse serum (Sigma-Aldrich Química SA, Madrid, Spain), L-glutamine (2mM final 
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concentration, Lonza BioWhittaker, Verviers, Belgium), 0.5 mL of fluconazole (Diflucan® 2mg/mL 
infusion, Pfizer, Amboise, France) and 5 mL of Penicillin-Streptomycin Solution Stabilized (cat.no. 



















2 - Methods: 
2.1 Determination of minimum inhibitory concentrations (MIC) of bacteria 
MICs of the 30 hydantoin derivatives (SZ-2, SZ-7, LL-9, BS-1, JH-63, MN-3, TD-7k, GG-5k, P3, 
P7, P10, P11, RW-15b, AD-26, RW-13, AD-29, KF-2, PDPH-3, Mor-1, KK-XV, Thioam-1, 
JHF-1, JHC-2, JHP-1, Fur-2, GL-1, GL-7, GL-14, GL-16, GL-18) against Salmonella 
Enteritidis NCTC 13349, wild-type Escherichia coli K-12 AG100 (argE3 thi-1 rpsL xyl mtl delta 
(gal-uvrB)  supE44), Staphylococcus aureus ATCC 25923 and Enterococcus faecalis ATCC 29212  
were assessed by the broth microdilution method, in 96-well microplates, according to the CLSI 
guidelines (CLSI, 2006). The bacterial strains were incubated overnight, at 37°C in 5 ml of Mueller 
Hinton broth (MHB). The inoculums used for MIC determination were prepared by adjusting the 
optical density of the culture to the 0.5 McFarland standard. The bacterial suspension was diluted to 
10-3 in Mueller Hinton broth (10 µL of inoculum in 10 mL of MHB). Aliquots of 100 µL of the 
diluted inoculum were then dispensed to each well of the microplate that contained serial two-fold 
dilutions of the compounds, starting from 500 µg/mL of final concentration. The final volume was 
200 µL in each well. The microplates were then incubated at 37 ºC and the results registered after 
16 and 18 hours of incubation. In order to assure that the hydantoin derivatives did not affect the 
cellular viability, the concentrations used did not exceed ½ of the MIC. The MIC was defined as the 
lowest concentration of the agent that produced no detectable evidence of growth (turbidity). The 
MIC for each agent and bacterium was determined three times.  
2.2 Assay for antiproliferative and cytotoxic effect on mouse lymphoma cells  
The effects of increasing concentrations of the hydantoin derivatives on cell growth were tested in 
96-well flat-bottomed microtitre plates. The compounds were diluted in a volume of 100 µL in 
McCoy’s 5A medium. Then, 6x103 (for antiproliferative effect) or 2x104 cells (for cytotoxicity 
assay) in 50 µL of medium, respectively, were added to each well, with the exception of the 
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medium control wells. The culture plates were further incubated at 37°C for 72 h (antiproliferative 
effect assay) and for 24 h (cytotoxicity assay); at the end of the incubation period, 15 µL of MTT 
(thiazolyl blue tetrazolium bromide, Sigma, St. Louis, MO, USA) solution (from a 5 mg/mL stock) 
was added to each well. After incubation at 37°C for 4 h, 100 µL of 10 % sodium dodecyl sulfate 
(SDS, Sigma) in 0.01M HCl was measured into each well and the plates were further incubated at 
37°C overnight. The cell growth was determined by measuring the optical density (OD) at 550 nm 
(ref. 630 nm) with Multiscan EX ELISA reader (Thermo Labsystems, Cheshire, WA, USA). 
Inhibition of the cell growth was determined according to the formula: 












Where ID50 is defined as the inhibitory dose that reduces the growth of the compound- exposed cells 
by 50%.  
2.3 Real-time semi-automated fluorometric method: accumulation assay to monitor efflux 
pump activity in bacteria 
EB is widely used to quantify the transport across the envelope of the bacterial cell, because it 
generates a quantifiable signal. This signal is low outside and amplified inside the cell (VIVEIROS 
et al, 2010).  
To screen the efflux modulating effect of the thirty hydantoin derivatives in the four strains of 
bacteria, a semi-automated method was used that demonstrates and quantifies the accumulation of 
EB on a real-time basis, developed by Viveiros et al (VIVEIROS et al, 2008). This method was 
carried out using the real-time thermocycler Rotor-GeneTM 3000 (Corbett Research, Sydney, 
Australia). The instrument allows the selection of the excitation and emission wavelengths that for 
EB are 530 nm band-pass and 585 nm high-pass filters, respectively. The fluorescence was acquired 
in cycles of 60 seconds, at 37 ºC. 
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Bacteria were grown in the respective media until they reached the optical density (OD) of 0.6 (1 x 
108 CFU/mL, where CFU is colony forming unit), at 600 nm, which is their mid log phase. 
Staphylococcus aureus ATCC 25923 and Enterococcus faecalis ATCC 29212 were grown in TSB 
medium, in addition E. coli AG 100 and Salmonella Enteritidis NCTC 13349 were grown in MHB. 
In order to remove the medium, the cultures were centrifuged for 3 minutes at 13000 rpm and 
washed twice in PBS. The final OD600 was adjusted to 0.6. Aliquots of 48 µL were transferred to 
0.2 mL microtubes. Different concentrations of EB were added to PBS and used in aliquots of 48 
µL: for Staphylococcus aureus ATCC 25923 the final concentration of EB was 0.25 µg/mL 
(COUTO et al, 2008), for Enterococcus faecalis ATCC 29212 the final concentration was 0.5 
µg/mL (SPENGLER et al, 2009a), for E. coli AG 100 the final concentration was 1 µg/mL 
(VIVEIROS et al, 2009) and for Salmonella Enteritidis NCTC 13349 the final concentration was 1 
µg/mL (AMARAL et al, 2010). Then 5 µL of the stock solutions of the compounds were added to 
the cells at three different concentrations (40, 80 and 120 µg/mL), individually. The tubes were then 
placed into the RotorGene 3000TM thermocycler (Corbett Research, Sydney, Australia), which 
provides, on a real-time basis, the assessment of transport kinetics of EB accumulation. The data 
obtained were analysed by Rotor-Gene Analysis Software 6.1 (Build 93) by Corbett Research 
(Sydney, Australia). Each accumulation assay was performed three distinct times. 
From the real-time data, the relative final fluorescence (RFF) of the last time point (minute 60) of 
the EB accumulation assay was calculated according to the formula: 
Activity of the compound (RFF) =   
                                                          
The relative final fluorescence (RFF) value is the difference between the relative fluorescence (RF) 
at the last time point of the EB retention curve of cells in the presence of the inhibitor and the RF at 
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the last time point of the EB retention curve of the untreated solvent control, divided by the 
untreated solvent control. The solvent used in the assays was DMSO. 
The mean of RFF of the three independent assays was calculated for each compound at different 
concentrations (40, 80 and 120 µg/mL). 
 
2.4 Real-time semi-automated fluorometric method: accumulation assay to monitor ABCB1 
(P-glycoprotein) pump activity in mouse lymphoma cells 
The cells were adjusted to a density of 2 x 610 cells/mL, centrifuged at 2000 x g for 2 minutes and 
resuspended in PBS. The cell suspension was distributed in 90 µL aliquots into 0.2 mL tubes. 
Volumes of 5 µL of the tested compounds stock solutions were added at different concentrations (4 
and 40 µg/mL) individually, and the samples incubated for 10 minutes at room temperature. After 
this incubation, 5 µL (1 µg/mL final concentration) of EB were then added to the samples and the 
tubes were placed in the Rotor-GeneTM 3000 and the fluorescence monitored on a real-time basis. 
Prior to the assay, the instrument was programmed for temperature (37 ºC), the appropriate 
excitation and emission wavelengths of EB (530 nm of band-pass and 585 nm high-pass, 
respectively). The fluorescence was acquired in cycles of 60 seconds. The data obtained were 
analysed by Rotor-Gene Analysis Software 6.1 (Build 93) by Corbett Research (Sydney, Australia). 
Each accumulation assay was performed three distinct times. The RFF values were calculated 
according to the formula: 
Activity of the compound (RFF) =   
The relative final fluorescence (RFF) value is the difference between the relative fluorescence (RF) 
at the last time point of the EB retention curve of cells in the presence of the inhibitor and the RF at 
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the last time point of the EB retention curve of the untreated solvent control, divided by the 
untreated solvent control. The solvent used in the assays was DMSO. 
The mean of the three independent experiments was calculated for each compound at two 
concentrations (4 and 40 µg/mL).
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IV - RESULTS 	  
1 - Multidrug resistance in bacteria 
One of the main mechanisms of antibacterial resistance is the prevention of antimicrobials from 
reaching their intended targets in bacterial cells. Decreased permeability, due to the 
lipopolysaccharides present in the outer membrane, or decrease of porins (restricted to Gram-
negatives), and the increasing efflux of drugs by overexpressed efflux pumps, contribute to the 
emergence of MDR phenotypes in clinical isolates. In contrast to the decreased permeability that 
prevents the entrance of drugs into bacteria, EPs extrude a wide range of noxious agents, such as 
toxins or antimicrobials (VIVEIROS et al, 2010). 
Fluorometry has been used to detect and quantify the transport of fluorescent substrates, such as 
EB, across the cell wall of bacteria. The use of fluorescent substrates, such as rhodamine 123, was 
the basis upon which flow cytometry became a worldwide recognized technique (VIVEIROS et al, 
2010; DAVEY & KELL, 1996).    
EB has been demonstrated to be appropriate as a probe for these experiments because emits weak 
fluorescence outside the cells (aqueous solution) and becomes strongly fluorescent inside the cells, 
as this is a nonpolar and hydrophobic environment (VIVEIROS et al, 2010).  
To screen the efflux pump modulating effect of the thirty hydantoin derivatives, a semi-automated 
method was used, developed by Viveiros et al (VIVEIROS et al, 2008).  The aim of this method is 
to easily and accurately detect and quantify the transport of EB through the bacterial cell wall, at 
working concentrations that do not affect cell viability or the cellular function. This method allows 
the real-time assessment of the balance between accumulation of EB through passive diffusion and 
extrusion via efflux of the substrate, allowing the monitoring of the efflux of substrates that are 
accumulated by a large population of cells. 
49	  
	  
 The semi-automated fluorometric method can be employed to compare intrinsic and over-
expressed efflux systems of bacteria, presenting advantages comparing to the flow cytometry. It is 
user-friendly, provides real-time assessment of the activity of the modulators and uses an 
inexpensive substrate, i.e. EB. However, the semi-automated fluorometric method is less sensitive 
than the flow cytometry (VIVEIROS et al, 2010;	  BREHM-STECHER & JOHNSON, 2004). 
2 - Accumulation of EB by bacterial efflux systems 
To screen the efflux pump modulating activity of the thirty hydantoin derivatives in bacteria, four 
well characterized reference strains were used. Two Gram-positive and two Gram-negative strains 
were tested: Staphylococcus aureus ATCC 25923 and Enterococcus faecalis ATCC 29212, 
Salmonella Enteritidis NCTC 13349 and Escherichia coli AG100, respectively.  
The selection criterion was the different cell wall structure that is much more permeable in Gram-
positives. Therefore, a semi-automated real-time fluorometric method was performed that 
demonstrates and quantifies the accumulation of EB on a real-time basis (VIVEIROS et al, 2008). 
In order to test the thirty hydantoin derivatives, concentrations were chosen that did not exceed ½ of 
the MIC of the compounds against Salmonella Enteritidis NCTC 13349, Escherichia coli AG100, 
Staphylococcus aureus ATCC 25923 and Enterococcus faecalis ATCC 29212. Thus, three different 
concentrations were applied in fluorometry such as 40, 80 and 120 µg/mL.  
MIC is considered the “gold standard” method for the determination of the susceptibility of 
microorganisms to antimicrobials. It is defined as the lowest concentration at which an 
antimicrobial inhibits the visible growth of a microorganism after overnight incubation, it means 
that the growth of the microorganisms has to be read after the 16th and 18th hour (CLSI, 2006). 	  
The MICs of EB and the thirty hydantoin derivatives were determined by broth microdilution 
method to ensure that the concentrations of each agent employed for assessment of their ability to 
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affect accumulation of EB would be well below that which affects the replication of the strains 
studied, furthermore the concentrations of the efflux pump modulator hydantoins would not affect 
the viability of the cells.  
The exact MIC could not be determined because of the precipitation in Mueller-Hinton medium 
showed by SZ-2, SZ-7, BS-1, JH-63, MN-3, P7, P10, AD-26, RW-13, AD-29, KF-2, Thioam-1 
and JHC-2 at high concentrations, furthermore the amount of compounds available was limited. 
The MICs of the compounds were above 500 mg/L for all the strains studied. 	  
The relative final fluorescence (RFF) value permits the comparison of the inhibitory effect of 
hydantoin derivatives at the last time point, i.e. minute 60. It is the difference between the relative 
fluorescence (RF) at the last time point (minute 60) of the EB retention curve of cells in the 
presence of the inhibitor and the RF at the last time point of the EB retention curve of the untreated 
solvent control, divided by the RF of the solvent control. The RF values were obtained from the 
real-time data.  
Compounds that showed RFF values above zero were considered effective in the inhibition or 
modification of efflux pump activity. Compounds that presented a RFF value equal to zero had no 
effect on the EB accumulation, furthermore, hydantoin derivatives that demonstrated RFF values 
under zero were considered not effective because of the possible interference with other cell 
functions or increase in efflux. In order to select the best compounds, hydantoin derivatives that 
demonstrated RFF values over 0.3 were considered the most effective ones. 
In this work, reference strains were used, as models of the intrinsic efflux pump systems of bacteria. 
The RFF values of the accumulation of EB were calculated and compared in the presence of the 
hydantoin derivatives. The EB concentrations used in the present study differed based on previous 
studies. The EB concentrations applied were as follows: Salmonella Enteritidis NCTC 13349 1 
µg/mL (AMARAL et al, 2010), E. coli AG 100 1 µg/mL (VIVEIROS et al, 2008), Staphylococcus 
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aureus ATCC 25923 0. 25 µg/mL (COUTO et al, 2008) and Enterococcus faecalis 29212 0.5 
µg/mL) (SPENGLER et al, 2009a). 
The thirty derivatives have also been tested in order to detect their auto-fluorescence and interaction 
with ethidium bromide. The compounds were applied at the highest concentration (120 µg/mL) in 
the presence and absence of EB in PBS. From the thirty hydantoin derivatives studied, SZ-7 
interacted with EB, presenting fluorescence intensity of 30 arbitrary units.  
Since the semi-automated fluorometric method analyses the balance between accumulation and 
efflux of EB, all the assays were performed in comparison to two different controls: one that 
contains the inoculum and EB, and the other with one containing the inoculum, EB and DMSO 














2.1 Effect of hydantoins on Gram-negative bacteria 
2.1.1 Accumulation of EB by Salmonella Enteritidis NCTC 13349 
Table 6. Relative final fluorescence (RFF) based on the accumulation of EB (1 µg/mL) by Salmonella Enteritidis 
NCTC 13349 in the presence of hydantoin derivatives.  
 
The RFF values of the accumulation of EB (1 µg/mL) in the presence of hydantoin compounds on 
Salmonella Enteritidis NCTC 13349 are shown in Table 6.
Relative Final Fluorescence (RFF) 
Salmonella Enteritidis NCTC 13349 
Compounds 
 
40 µg/mL 80 µg/mL 120 µg/mL 
Thioam-1 1.1 0.8 1.0 
SZ-2 0.7 2.1 2.8 
P3 0.5 1.1 1.4 
RW-15b 0.4 1.0 0.9 
AD-26 0.4 0.8 0.4 
GL-7 0.3 0.4 0.6 
AD-29 0.3 0.5 0.3 
GL-18 0.2 0.5 0.4 
P7 0.2 0.3 0.3 
Fur-2 0.2 -0.1 -0.1 
GL-16 0.2 0 0 
MN-3 0.1 0.2 0.4 
JHC-2 0.1 0.2 0.3 
Mor-1 0.1 0.2 0.1 
JHF-1 0.1 0.1 0 
JHP-1 0.1 -0.1 -0.1 
GL-1 0.1 -0.1 -0.1 
SZ-7 0 1 3.7 
KK-XV 0 0 -0.1 
KF-2 0 0 0.1 
JH-63 0 0.3 0.5 
BS-1 0 0.1 0.1 
GG-5k 0 -0.2 -0.2 
P10 -0.1 0.2 0.2 
RW-13 -0.1 0 -0.1 
PDPH-3 -0.1 0.1 -0.1 
TD-7k -0.1 -0.1 -0.1 
GL-14 -0.1 -0.1 -0.2 
LL-9 -0.1 0.1 -0.1 
P11 -0.3 -0.1 0 
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As demonstrated by Table 6, the most effective compounds are the following: Thioam-1, SZ-2, P3, 
RW-15b, SZ-7, AD-26, AD-29, GL-7, GL-18 and P7. These derivatives significantly increased the 
retention of EB inside the cells. Furthermore, SZ-7 was the most potent inhibitor, as demonstrated 
by the ranking (Table 6), especially when used at 120 µg/mL. 
Figure 12. Accumulation of EB (1µg/mL) in the presence of SZ-7 (40, 80 and 120 µg/mL) on  
Salmonella Enteritidis NCTC 13349.  
 
As evident from Figure 12, in the presence of SZ-7, the accumulation of EB was increased, as 
compared to the controls, where the modulator was not present. The effect of SZ-7 on EB 
accumulation was dose-dependent, namely the increasing accumulation of EB is proportional to the 
increasing concentrations of the compound. 
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Figure 13. Accumulation of EB (1µg/mL) in the presence of P3 (40, 80 and 120 µg/mL) on Salmonella Enteritidis 
NCTC 13349.  
 
As revealed by Figures 13 and 14, P3 and SZ-2 possessed good efflux modulating effect, 
respectively. Among the derivatives studied, Thioam-1 and RW-15b increased significantly the 
accumulation of EB. In addition, AD-26, GL-7, AD-29, GL-18 and P7 were also active and can be 
good candidates for further studies. 




2.1.2 Accumulation of EB by Escherichia coli AG 100 
 
Table 7.  Relative final fluorescence (RFF) based on the accumulation of EB (1 µg/mL) by E. coli AG100 in the 
presence of hydantoin derivatives.  
Relative Final Fluorescence (RFF) 









AD-29 1.7 1.6 1.2 
RW-15b 1.5 1.1 1.3 
AD-26 1.1 1.0 1.2 
Thioam-1 1.0 0.5 0.4 
GL-18 0.6 0.7 0.8 
P3 0.5 1.0 1.3 
KF-2 0.4 0.5 0.4 
SZ-2 0.3 0.6 0.7 
RW-13 0.3 0.3 0.3 
BS-1 0.3 0.2 0.2 
GL-16 0.3 0.2 0 
JH-63 0.2 1.2 1.3 
P10 0.2 0.2 0.3 
PDPH-3 0.2 0.2 0.3 
Mor-1 0.2 0.2 0.3 
KK-XV 0.2 0.1 0 
MN-3 0.1 0.9 1.0 
P7 0.1 0.2 0.4 
JHC-2 0.1 0.2 0.3 
GL-7 0.1 0.2 0.3 
P11 0.1 0.2 0.2 
LL-9 0 0.8 0.5 
JHP-1 0 0 -0.1 
GL-1 0 0 0 
JHF-1 0 0 -0.1 
Fur-2 0 0 0.1 
GL-14 0 -0.1 -0.1 
TD-7k 0 0 0 
GG-5k 0 0 0 
SZ-7 -2.4 -1.6 -0.3 
	  
Table 7 presents the RFF values of the accumulation of EB (1 µg/mL) in the presence of hydantoin 
derivatives on E. coli AG100. 
56	  
	  
As demonstrated in Table 7, almost all of the compounds were effective in efflux pump modulation. 
In addition, the most effective compounds were AD-29, RW-15b, AD-26, Thioam-1, GL-18, P3, 
KF-2 and RW-13. According to Table 7, SZ-2, JH-63 and MN-3 had also remarkable activity. 
Figure 15. Accumulation of EB (1µg/mL) by E. coli AG 100 in the presence of AD-29 (40, 80 and 120 µg/mL). 
 
As demonstrated in Figure 15, AD-29 effectively inhibited the efflux of EB, however it was more 
effective at low concentration. Compound Thioam-1 showed similar characteristics, because it was 












Figure 16. Accumulation of EB (1 µg/mL) by E. coli AG 100 in the presence of  RW-15b (40, 80 and 120 µg/mL). 
 
As shown by Figure 16, RW-15b, that is one of the compounds with higher ranking, caused EB 
accumulation, demonstrating thus modulating effect
  
 
As evident from Figure 17, AD-26 effectively inhibited the extrusion of EB compared to the 
controls, moreover the RFF values were similar for all the three concentrations applied, indicating 
that the compound might be active at lower concentrations. 




2.2. Effect of hydantoins on Gram-positive bacteria 
 
2.2.1 Accumulation of EB by Staphylococcus aureus ATCC 25923 
Table 8. Relative final fluorescence (RFF) based on the accumulation of EB (0.25 µg/mL) by Staphylococcus 
aureus ATCC 25923 in the presence of hydantoin derivatives.  
 
 The ranking of compounds based on RFF values of the accumulation of EB (0.25 µg/mL) in the 
presence of the thirty hydantoin derivatives is demonstrated in Table 8. As shown by Table 8, the 
majority of the hydantoin compounds were not effective on Staphylococcus aureus ATCC 25923.  
Relative Final Fluorescence (RFF) 
Staphylococcus aureus ATCC 25923	  
Compounds 
 
40 µg/mL 80 µg/mL 120 µg/mL 
GL-18 0.5 0.7 0.8 
MN-3 0.4 0.2 0.2 
GL-16 0.3 0.3 0.3 
TD-7K 0.2 0 0.1 
Sz-2 0.2 -0.1 -0.1 
GG-5K 0.2 -0.1 -0.2 
GL-14 0.1 0 0.1 
AD-26 0.1 -0.1 -0.2 
Sz-7 0.1 -0.3 0.3 
GL-7 0 0 0.1 
P10 0 -0.3 -0.1 
P11 0 -0.1 -0.1 
JHC-2 0 0 0 
JH-63 0 -0.2 -0.2 
KF-2 -0.1 -0.1 0 
BS-1 -0.1 -0.1 -0.1 
P3 -0.1 -0.1 -0.2 
Mor-1 -0.1 -0.3 -0.1 
LL-9 -0.1 -0.3 -0.2 
AD-29 -0.1 -0.4 -0.2 
GL-1 -0.2 -0.1 0.1 
Fur-2 -0.2 -0.2 -0.1 
PDPH-3 -0.2 -0.2 -0.2 
JHF-1 -0.3 0 -0.1 
JHP-1 -0.3 -0.1 -0.2 
KK-XV -0.3 -0.1 -0.2 
P7 -0.3 -0.1 -0.3 
RW-15b -0.3 -0.3 -0.3 
RW-13 -0.3 -0.4 -0.3 
Thioam-1 -0.3 -0.7 -0.8 
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GL-18 (shown by Figure 18) was the most potent inhibitor, furthermore GL-16 and MN-3 could 
modify the efflux activity of the strain, promoting the retention of EB inside the cells. 
Figure 18. Accumulation of EB (0.25 µg/mL) in the presence of SZ-7 (40, 80 and 120 µg/mL) on Staphylococcus 






2.2.2 Accumulation of EB by Enterococcus faecalis ATCC 29212 
 
Table 9. Relative final fluorescence (RFF) based on the accumulation of EB (0.5 µg/mL) by Enteroccocus faecalis 
ATCC 29212 in the presence of hydantoin derivatives.  	  
Relative Final Fluorescence (RFF) 
Enterococcus faecalis ATCC 29212 
Compounds 
 
40 µg/mL 80 µg/mL 120 µg/mL 
GL-14 0.3 0.8 1.1 
LL-9 0.3 0.1 -0.1 
P3 0.2 0.4 0.3 
JHF-1 0.2 0.2 0.1 
SZ-2 0.2 0 0.1 
BS-1 0.2 0 0.1 
MN-3 0.1 0.1 0.1 
JHP-1 0.1 0.2 0.2 
JHC-2 0.1 0.1 0.2 
Fur-2 0.1 0.1 0.1 
GL-1 0.1 0.1 0 
GL-7 0 0.2 0.5 
P7 0 0.2 0 
GL-16 0 0 0.2 
GG-5k 0 0 0 
KK-XV 0 0 0 
JH-63 0 -0.2 -0.1 
Mor-1 -0.1 0.1 0.1 
PDPH-3 -0.1 0 0.1 
KF-2 -0.1 0.1 -0.1 
P10 -0.1 0 0 
TD-7k -0.1 0 0 
AD-29 -0.1 0 -0.1 
AD-26 -0.1 -0.1 -0.1 
Thioam-1 -0.1 -0.3 -0.5 
RW-15b -0.2 -0.3 -0.3 
GL-18 -0.2 -0.1 0.2 
P11 -0.2 -0.2 -0.2 
RW-13 -0.3 -0.2 -0.2 
SZ-7 -1.2 -0.7 0.1 
 
Table 9 demonstrates the RFF values of the accumulation of EB (0.5 µg/mL) in the presence of the 




As shown by Table 9, GL-14 and GL-7 inhibited the extrusion of EB in a dose dependent manner. 
Compound P3 showed slight efflux modulating effect.	   
Figure 19. Accumulation of EB (0.5 µg/mL) in the presence of GL-14 (40, 80 and 120 µg/mL) on Enterococcus 
faecalis ATCC 29212. 
 
As indicated in Figure 19, compound GL-14 modified the retention of EB, furthermore GL-14 was 
more active compared to GL-7, indicating the importance and the position of the –COOH group.
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3 - Efflux pump modulating activity of hydantoin derivatives on cancer cells 
 
Resistance to chemotherapy is a big concern in the treatment of cancer. As chemotherapy is the 
treatment of choice for ~50% of all types of cancer, acquired resistance to chemotherapy must be 
studied (AMBUDKAR et al, 2005). 
Overexpression of drug transporters such as ABCB1 (P-gp) is the main mechanism by which cancer 
cells avoid the toxic effects of chemotherapeutic drugs. The clinical importance of ABCB1 derives 
from the fact that over-expression of P-gp is often associated with multidrug resistance. 
In order to reduce the ABCB1 related consequences in the failure of chemotherapy, the 
development of potent but nontoxic inhibitors is fundamental. Because of the importance of 
ABCB1, the screening of ABCB1 modulating agents has to be incorporated into the drug discovery 
process. 
Flow cytometry is the standard method to screen P-gp modulators (ARCECI, 1993). In this method 
the substrate used is rhodamine 123. Therefore, the aim of this assay is to find P-gp modulators that 
inhibit the extrusion of rhodamine 123. The method is very sensitive but does not provide a real-
time assessment of the modulator, uses a very expensive instrument and needs a well experienced 
technician. For this purpose, Spengler et al developed a new fluorometric method (SPENGLER et 
al, 2009b) based on the previously described semi-automated method used to monitor bacterial 
efflux systems (VIVEIROS et al, 2008). 
The fluorometric method (SPENGLER et al, 2009b) has been applied to assess the activity of 
ABCB1 in multi-drug resistance (MDR) T-lymphoma cells transfected with the human ABCB1 
gene, which overexpress the ABCB1 transporter, and in parental (PAR) T-lymphoma cell line, 
showing normal ABCB1 expression level. The fluorometric method allows the comparison of 
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ABCB1 modulators and screen their effect in cells with normal and overexpressed ABCB1 efflux 
activity.  In contrast to the flow cytometry, this new method uses etidium bromide (EB) instead of 
rhodamine 123. EB is a common substrate of bacterial efflux transporters and P-glycoprotein and an 
inexpensive fluorochrome. The semi-automated fluorometric method assesses the EB accumulation 
in various cells and in a real-time manner, contrasting to the flow cytometry that assesses 
rhodamine 123 accumulation at one point of time in the cell population. However, flow cytometry 
is much more sensitive and presents different cell populations in contrast to the fluorometric method 
that shows the bulk signal of the population.  
 
3.1 Antiproliferative and cytotoxic effects of hydantoin derivatives on L5178 (parental, PAR) 
mouse T-cell lymphoma cells and its human ABCB1 (MDR1)-transfected subline (MDR) 
 
MTT assay to assess cell proliferation and cytotoxicity 
The MTT ((3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay is based on the 
metabolic activity of the cells and is widely used to quantify cell proliferation and cytotoxicity. 
The principle of the MTT assay is that the tetrazolium ring in MTT is cleaved by dehydrogenases 
present in active mithocondria of the metabolically active cells, producing an insoluble MTT 




Table 10. Antiproliferative and cytotoxic effects of hydantoin derivatives on L5178 (parental, PAR) mouse T-cell 
















SZ-2a* 25.61 48.33 29.40 67.12 
SZ-7b* 4.54 3.84 4.60 4.41 
LL-9 54.19 54.12 64.49 54.19 
BS-1c* 15.21 60.07 8.6 16.42 
JH-63d* 15.24 28.09 14.99 27.62 
MN-3e* 10.55 16.97 8.24 13.89 
TD-7k 107.73 237.94 141.09 198.47 
GG-5k 72.66 151.23 99.88 203.77 
P3 19.33 28.09 12.6 12.38 
P7f* 87.13 18.15 30.85 43.77 
P10g* 112.09 286.50 56.31 89.65 
P11 118.77 115.71 101.05 190.52 
RW-15b 53.42 37.97 31.17 44.48 
AD-26h* 33.19 31.33 10.32 13.24 
RW-13i* 11.95 19.12 5.31 14.83 
AD-29j* 39.42 19.48 11.38 6.43 
KF-2 71.99 82.31 54.34 70.08 
PDPH-3 90.10 99.36 23.84 16.00 
Mor-1 76.80 240.24 34.92 120.22 
KK-XV 78.67 245.56 84.95 171.27 
Thioam-1k* 5.272 3.92 4.65 6.85 
JHF-1 111.59 225.71 94.14 192.88 
JHC-2 84.78 143.80 53.52 135.80 
JHP-1** N.D. N.D. N.D. N.D. 
Fur-2 94.64 426.01 91.01 283.76 
GL-1 92.48 187.74 94.21 296.11 
GL-7 47.34 313.42 53.36 174.09 
GL-14 78.78 276.72 88.37 212.73 
GL-16 100.99 208.35 102.42 206.16 
GL-18 86.69 443.95 82.02 295.34 
DMSO 1.09 % 2.39 % 1.04 % 6.17% 
*precipitation, crystal-formation: a amorphous crystals, b amorphous crystals, c needle-like crystals,d amorphous 
crystals, e amorphous crystals, f oval crystals, g pine-leaf-like crystals, h amorphous crystals, i amorphous crystals, j 
needle-like crystals, k amorphous crystals 
**complex formation with MTT in McCoy’s 5A, IC50  non-determinable. 
 
The compounds were tested for antiproliferative and cytotoxic effect against L5178 mouse T-cell 
lymphoma cells (parental, PAR) and its human ABCB1 (MDR1)-transfected subline (MDR). 
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As demonstrated in Table 10, from the listed compounds, SZ-7 and Thioam-1 showed the strongest 
antiproliferative and cytotoxic effect on PAR and MDR cells as well. The concentrations required 
to inhibit 50% of cell growth are shown in Table 10. 
As demonstrated by Figure 20 and depicted by Table 10, some of the compounds showed 






















3.2 Accumulation assay of EB in efflux systems of cancer cells 
The optimum concentration of EB for studying real-time accumulation on L5178 (parental, PAR) 
mouse T-cell lymphoma cells and its human ABCB1 (MDR1)-transfected subline (MDR) is 1 
µg/mL. This concentration permits the study of EB accumulation in the presence of EPIs without 
affecting the cell viability (SPENGLER et al, 2009b).   
The semi-automated fluorometric method analyses the balance between accumulation and efflux of 
EB. All the assays were performed in comparison to two different controls: one that contains the 
untreated cells, PAR or MDR plus EB, and the other one containing PAR or MDR cells, EB and 
DMSO which is the solvent of the compounds. 
The relative final fluorescence (RFF) value permits the comparison of the hydantoin derivatives on 
ABCB1 inhibition. The RFF is the difference between the relative fluorescence (RF) at the last time 
point (minute 60) of the EB retention curve of cells in the presence of the inhibitor and the RF at the 
last time point of the EB retention curve of the untreated solvent control, divided by the RF of the 
solvent control. The RFF values were obtained from the real-time data.  
Compounds that showed RFF values above zero were considered effective in the inhibition or 
modification of ABCB1. Compounds that presented a RFF value equal to zero had no effect on the 
EB accumulation and hydantoin derivatives that demonstrated RFF values under zero were 
considered not effective because they increased the efflux activity or modified other cell functions. 
In order to select the best compounds, hydantoin derivatives that demonstrated RFF values over 0.3 
were considered the most effective.  
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Table 11. Relative final fluorescence (RFF) based on the accumulation of EB (1 µg/mL) by PAR cells in the 
















As demonstrated in Table 11, some of the hydantoin derivatives could modify the activity of 
ABCB1. The most effective ones were the following: AD-29, KF-2, Thioam-1, Fur-2, Mor-1, 
MN-3, JHC-2, JH-63, SZ-7 and PDPH-3. 
 




4 µg/mL 40 µg/mL 
AD-29 0.6 0.4 
KF-2 0.6 0	  
Thioam-1 0.6 -0.2	  
Fur-2 0.5 0.1	  
Mor-1 0.5 -0.1 
MN-3 0.4 0.9	  
JHC-2 0.3 0	  
P3 0.2 0.4	  
BS-1 0.2 0.2	  
P7 0.2 0.2	  
P11 0.2 0.2	  
TD-7K 0.2 0	  
JH-63 0.1 0.9	  
SZ-7 0.1 0.6	  
JHF-1 0.1 0	  
GG-5K 0.1 -0.1	  
PDPH-3 0 0.7	  
SZ-2 0 0.2 
GL-7 0 0.1	  
P10 0 0	  
AD-26 0 -0.1	  
GL-1 0 -0.1	  
RW-13 -0.1 0.1	  
GL-14 -0.1 0.1	  
LL-9 -0.1 0	  
JHP-1 -0.1 -0.1	  
GL-18 -0.2 0	  
RW-15b -0.2 -0.1	  
KK-XV -0.3 -0.2	  
GL-16 -0.3 -0.3	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3.2.1 Effective compounds on PAR cells 
As seen in Table 11, AD-29, KF-2, Thioam-1, MN-3 and JH-63 were the most effective 
compounds.  
 
Figure 21.  Accumulation of EB (1 µg/mL) in the presence of Thioam-1 (4 and 40 µg/mL) on PAR cells.  
The activity of the hydantoin derivatives can be demonstrated by the example of two derivatives 
such as Thioam-1 and Fur-2. 
As presented in Figure 21, at low concentration (4 µg/mL), Thioam-1 was more effective in 
contrast to the characteristics presented by this modulator at high concentration (40 µg/mL). 
Compound Fur-2 showed the same activity, because it was more effective at low concentration 
than at 40 µg/mL (Figure 22). 
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Table 12. Relative final fluorescence (RFF) based on the accumulation of EB (1 µg/mL) by MDR cells in the 
















As presented in Table 12, the majority of the hydantoin derivatives effectively inhibited the 
extrusion of EB in MDR cells, such as PDPH-3, GL-7, KK-XV, AD-29, Thioam-1, SZ-7, KF-2, 
MN-3, RW-13, LL-9, P3, GL-1, TD-7K, AD-26, GL-18, SZ-2, JH-63, BS-1 and RW-15b. 
 




4 µg/mL 40 µg/mL 
GL-7 0.9 0 
PDPH-3 0.8 0.8 
KK-XV 0.8 0.3 
AD-29 0.7 1.1 
Thioam-1 0.7 0.1 
SZ-7 0.6 1.6 
KF-2 0.6 0.4 
MN-3 0.5 0.7 
RW-13 0.4 1.5 
LL-9 0.4 0.3 
P3 0.4 0.3 
GL-1 0.3 0.2 
TD-7K 0.3 -0.1 
Mor-1 0.2 0 
AD-26 0.1 0.4 
GL-18 0.1 0.3 
SZ-2 0.1 0.3 
JHP-1 0.1 0.2 
GL-14 0.1 0.2 
JHF-1 0.1 0.1 
GL-16 0.1 -0.2 
JH-63 0 0.7 
GG-5K 0 0.2 
P10 0 0.1 
JHC-2 0 -0.4 
P11 -0.1 0 
Fur-2 -0.1 0 
P7 -0.2 -0.2 
BS-1 -0.2 0.4 
RW-15b -0.3 1.3 
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3.2.2 Effective compounds on MDR cells 
As presented in Table 12, RW-13, RW-15b, AD-29 and SZ-7 were the most effective compounds 
in MDR cells.  
Figure 23. Accumulation of EB (1 µg/mL) in the presence of RW-15b (4 and 40 µg/mL) on MDR cells. 
As demonstrated in Figure 23, RW-15b effectively inhibited the extrusion of EB by ABCB1 in 












Figure 24. Accumulation of EB (1 µg/mL) in the presence of RW-13 (4 and 40 µg/mL) on MDR cells. 
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As evident from Figure 24, RW-13 was very effective promoting the accumulation of EB, 
furthermore this derivative could inhibit the activity of ABCB1 in a dose-dependent manner. 
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3.2.3 Effective compounds on MDR and PAR cells 
As shown by Figures 25, 26 and 27, there were some compounds effective on PAR and MDR cells 
as well: PDPH-3, AD-29, Thioam-1, SZ-7, KF-2, MN-3 and JH-63.
Figure 25.  Accumulation of EB (1µg/mL) in the presence of AD-29 (4 and 40 µg/mL) on PAR (A) and MDR (B) 
cells. 
 
As demonstrated by Figure 25 (A and B), AD-29 was more effective on MDR cells, however it had 
a slight effect on PAR cells as well. 
74	  
	  
The data obtained confirmed the fact that AD-29 is more selective for the MDR cells which 
overexpress ABCB1. 
 




As demonstrated in Figure 26 (A and B), MN-3 promoted the accumulation of EB in PAR and 
MDR cells as well. This compound caused EB accumulation in a dose-dependent manner and was 




Figure 27.  Accumulation of EB (1 µg/mL) in the presence of JH-63 (4 and 40 µg/mL) on PAR (A) and MDR (B) 
cells.  




V – DISCUSSION AND CONCLUSIONS 
1.1 - Evaluation of hydantoin derivatives on Gram-negative and Gram-positive bacteria 
The increasing prevalence of MDR bacteria is one of the great concerns to health care institutions. 
This, complemented with the reduced number of new agents entering the clinical practise, is 
recognised as a major threat to public health (www.dh.gov.uk). Over-expressed efflux pumps that 
extrude a variety of structurally unrelated antibiotics are associated with multidrug resistant (MDR) 
phenotypes in Gram-negative bacteria. Usually, the characterization of efflux activity has been 
essentially restricted to bacteria that overexpress efflux components (SPENGLER et al, 2009a). 
However, the intrinsic efflux pump apparatus of the wild type Gram-negative strain that produces 
infection provides the means by which the bacterium survives in different physiological conditions 
(MARTINS et al, 2009). 
In the present study, thirty hydantoin compounds were evaluated for their efflux modulating effects 
on the intrinsic efflux system of Gram-negative and Gram-positive bacteria via the use of an 
automated real-time fluorometric method that monitors the intracellular accumulation of ethidium 
bromide. 
Hydantoins play an important role in purine catabolic pathway that regulates the purine pool in the 
cell providing precursors for nucleic acid synthesis (AGARWAL et al, 2007). In addition, the 
nucleobase-cation-symport-1 (NCS1) transporters are essential components of salvage pathways for 
nucleobases and related metabolites, e.g. NCS1 benzyl-hydantoin transporter, Mhp1, from 
Microbacterium liquefaciens (WEYAND et al, 2008). 
Besides the biochemical processes, hydantoins have pharmacological properties and are used to 
treat many human diseases (THENMOZHIYAL et al, 2004; RAJIC et al, 2006). Furthermore, it 
has been demonstrated that 5-arylidene-2-thiohydantoins have in vitro antimycobacterial activity 




In our study, the tested hydantoin derivatives were more effective in the selected strains of Gram-
negative bacteria i.e. Salmonella Enteritidis NCTC 13349 and Escherichia coli AG 100 than in 
Gram-positives. In spite of their less permeable cell envelope, the tested compounds promoted the 
accumulation of EB in these bacterial cells. On the contrary, hydantoin derivatives were not 
effective on the EB accumulation in the selected Gram-positive bacteria. 
 The best compounds for each bacterial strain are summarized in Table 13. The hydantoin 
derivatives were selected based on their RFF values. Compounds that presented RFF values above 
0.3 were considered the most effective ones. 







The compounds Thioam-1, SZ-2, P3, RW-15b, AD-26, AD-29, GL-18, GL-7, KF-2, SZ-7, MN-
3, GL-16 and GL-14 promoted significantly the accumulation of EB in the selected bacterial 
strains. 
1.2 Future perspectives  
The real-time fluorometry is a very useful tool to screen a great number of compounds, in this case 
a series of hydantoin derivatives, because it provides information about transport kinetics thereby 
offers a rapid, high-throughput, reproducible, accurate and inexpensive screening of efflux pump 
inhibitors. 
Bacterial strains Compounds 
Salmonella Enteritidis NCTC 13349 Thioam-1, SZ-2, P3, RW-15b, AD-26, 
GL-7, AD-29, GL-18, P7 and SZ-7 
Escherichia coli AG 100 AD-29, RW-15b, AD-26, Thioam-1, 
GL-18, P3, KF-2, SZ-2 and RW-13 
Staphylococcus aureus ATCC 25923 GL-18, MN-3 and GL-16  
Enterococcus faecalis ATCC 29212 GL-14, P3 and GL-7 
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For further studies, different physiological conditions such as different pHs, temperatures and 
presence/absence of glucose should be investigated in order to mimic the natural environmental 
factors present in living organisms.  
It is well known that a cascade of hydantoinase, N-carbamoylase and hydantoinracemase can be 
used for the production of natural and unnatural chiral D - and L -amino acids from chemically 
synthesized hydantoin derivatives (ALTENBUCHNER et al, 2001). 
Concerning our study, we have no information about the metabolism, enzymatic modification or 
cleavage of the derivatives during the period of the assay. For further studies the role of temperature 
and pH should be elucidated, as well as the activity of the derivatives in bacteria having over-
expressed efflux pump systems. 
 
2.1 Evaluation of hydantoin derivatives on the activity of P-glycoprotein in mouse T-
lymphoma cells 
Multidrug resistance plays a crucial role in the failure of treatment of cancer. One such mechanism 
involves the cytoplasmic membrane-localised transport system, which takes part in normal 
physiological functions as well. In cancer patients, the main reason for treatment failure is the 
presence of resistance to the chemotherapy. The major mechanism of multidrug resistance is the 
elevated expression of ATP-dependent drug-efflux pumps, which reduce the accumulation of the 
anticancer agents. In many tumour cell lines, multidrug resistance is often associated with the over-
expression of ABC drug-transporter P-glycoprotein (P-gp), also known as ABCB1. The efflux of 
chemotherapeutic drugs caused by these transporters, reduce the cellular accumulation of these 




Hydantoin derivatives possess a wide range of biochemical effects as well as various 
pharmacological properties, e.g. anti-tumour activity (KUMAR et al, 2009). Although hydantoin 
compounds have been studied extensively, there are not many studies about their anticancer 
properties.  Recently, the cytotoxic activity of spirohydantoin derivatives was tested in ovarian and 
breast cancer cells (THENMOZHIYAL et al, 2004). It has been shown that a spirohydantoin 
derivative induces growth inhibition and apoptosis in leukemic cells (KAVITHA et al, 2009).  
In the present study, the majority of the tested compounds could inhibit the ABCB1 related 
resistance, causing increased accumulation of EB inside the cells. 
It was thus possible to evaluate the inhibition effect of the thirty hydantoin derivatives in L5178 
mouse T-cell lymphoma cells (parental, PAR) and its human ABCB1-gene transfected sub-line 
(MDR) overexpressing the ABCB1 transporter. The best compounds, based on their RFF values, 
are summarized in Table 14. The most effective hydantoin derivatives demonstrated RFF values 
over 0.3. 
Table 14. The most active hydantoin derivatives on parental (PAR) and multidrug resistant (MDR) human 







Previously, a semi-automated fluorometric method has been developed by Viveiros et al. that 
utilizes ethidium bromide (EB), a common substrate of bacterial efflux pumps (VIVEIROS et al, 
2008). The method is sufficiently sensitive to characterize the efflux pump systems of bacteria. 
Because EB is also recognized and extruded by ATP-binding-cassette (ABC) transporters, the 
method has been extended for the evaluation of agents that can inhibit the extrusion of EB on a real-
Cell line  Most effective compounds 
MDR PDPH-3, GL-7, KK-XV, AD-29, Thioam-1, SZ-7, KF-2, MN-3, 
RW-13, LL-9, P3, AD-26, JH-63 and RW-15b 




time basis by mouse lymphoma cells containing the human MDR1(ABCB1) gene (SPENGLER et 
al, 2009b). Using this method, four curcubitane-type triterpenes isolated from Momordica 
balsamina Linn. (Cucurbitaceae) were evaluated for their activity to inhibit the ABC transporter P-
glycoprotein in mouse lymphoma cells. The evaluation was conducted by flow cytometry using 
rhodamine 123 and real-time fluorometry that assesses accumulation of EB on a real-time basis 
(SPENGLER et al, 2009c). 
Based on these studies, a large number of compounds can be screened by real-time fluorometry and 
selected for further studies. 
In the present work, thirty hydantoin compounds were evaluated for their efflux modulating effects 
in cancer cells using real-time fluorometry based on the intracellular accumulation of ethidium 
bromide. 
It is important to note that many compounds precipitated at higher concentrations (> 100 mg/L) in 
the media used such as SZ-2, SZ-7, BS-1, JH-63, MN-3, P7, P10, AD-26, AD-29, RW-13 and 
Thioam-1. Since we applied the compounds at lower concentrations, this fact did not influence the 
outcomes of the experiments. 
The selected compounds were studied by fluorescence activated cell sorting (FACS) using 
rhodamine 123, a fluorochrome substrate of P-gp (SPENGLER et al, 2010). 
The mouse lymphoma cell line transfected with the human MDR1 gene that codes for the ABC 
transporter P-gp that is responsible for multidrug resistance of this cell line to cytotoxic agents, is a 
very useful model for evaluating agents that inhibit the activity of the transporter.  Among the 
hydantoin derivatives evaluated for potential inhibition of the P-gp transporter, BS-1, MN-3 and 
JH-63 were the most effective inhibitors at the concentration of 4 mg/L.  
Surprisingly, on MDR cancer cells the rhodamine 123 retention data did not always correlate with 
the ethidium bromide accumulation data in terms of the magnitude of activity.  In flow cytometry, 
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compound BS-1 was the most effective compound but in real-time fluorometry it had a slight effect 
on the inhibition of ABCB1. On the other hand, PDPH-3 and KK-XV seemed to be promising 
compounds in the real-time fluorometry, although they had less activity on rhodamine 123 retention 
in flow cytometry. A possible explanation can be the use of different P-gp subtrates (ethidium 
bromide and rhodamine 123) in different experimental conditions. 
From the most effective compounds, four compounds were chosen to determine their interaction 
with the anticancer drug doxorubicin. Compounds SZ-7, BS1, MN-3 and JH-63 were combined 
with doxorubicin on MDR1-gene transfected mouse lymphoma cells. Compounds BS-1, MN-3 and 
JH-63 showed synergistic effect with doxorubicin on mouse lymphoma cells, furthermore 
compound SZ-7 had indifferent effect with doxorubicin (SPENGLER et al, 2010). 
The most active structures contained aromatic substituents as well as some tertiary amine 
fragments. 
2.2 Future perspectives  
Hydantoin derivatives possess a wide range of pharmacological applications and are used to treat 
many human diseases. One such disease is epilepsy, characterized by the uncontrolled convulsions. 
The most known hydantoin derivative is phenytoin that is used since 1938 for the treatment of 
generalized tonic-clonic seizures (THENMOZHIYAL et al, 2004). 
Various aspects of the biochemical and pharmacological properties of hydantoin derivatives have 
been studied (THENMOZHIYAL et al, 2004; SOMSÁK et al, 2001). However, the anticancer 
activity of these compounds has received little attention. 
Based on the results obtained, compounds AD-26, AD-29, RW-13, KF-2, BS-1, MN-3, RW-15b 
and JH-63, should be studied for in vitro capability of reversing or reducing resistance of the mouse 
lymphoma MDR1 gene transfected cell to cytotoxic agents to which they are initially resistant.  
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To clarify the active group(s) of the hydantoin derivatives and to validate the ABC transporter 
targets we plan Qualitative Structure Activity Relationship (QSAR) studies in collaboration with 
French (UMR-MD1, Transporteurs Membranaires, Chimiorésistance et Drug Design, Faculté de 
Médecine, Marseille) and Polish (Department of Technology and Biotechnology of Drugs, 
Jagiellonian University Medical College, Kraków) research groups. 
With the purpose to explore the possibilities of the tested hydantoin derivatives, their activity on 
different cell lines should be of interest. We plan to investigate the activity of the hydantoin 
derivatives in other MDR cancer models, such as K562 human leukaemia cells with overexpressed 
P-gp (ABCB1) or colon carcinoma model using Colo 205/S sensitive colon carcinoma cells with 
normal ABCB1 expression pattern and Colo 320/R resistant colon carcinoma having overexpressed 
ABCB1 system.  
Active compounds are then to be examined in the mouse model for ability to shrink solid 
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